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 Cholera is it is estimated to infect millions of people every year resulting in over 
100,000 deaths annually.  There are two WHO pre-qualified oral cholera vaccines that are 
recommended for use in conjunction with other prevention and control strategies in 
endemic and outbreak areas.  There is currently a limited availability of vaccine supply, 
therefore, its use must be administered strategically.  This study sought to improve the 
understanding of cholera disease burden and outbreak risk worldwide through the 
development of simplified and sustainable tools for use in low resource settings.   
Methods 
 Data from 949 clinical diarrhea cases and 1,102 environmental specimens from 7 
Health Facilities were analyzed using simplified laboratory diagnostic methods to assess 
the cholera burden in the Far North of Cameroon.  V. cholerae 01 positive specimens were 
analyzed to determine the genetic relationship between geographically distinct areas in 
Cameroon. To further evaluate tools for determining disease burden, a rapid risk 
assessment tool (RAT) for cholera was developed and evaluated using surveillance data 
from the Republic of Kenya.   
Results 
 In the sentinel surveillance study, the simplified laboratory diagnostics identified 
outbreaks early and with no false positive results.  Sequencing revealed that outbreak 
specimens from the Bourrha Health district in June of 2014 were related to outbreak 
specimens from Darak and Blangoua Health districts in October of 2014.  The cholera RAT 
 ii 
identified a few key districts in Kenya where implementation of cholera interventions, to 
include vaccination, may be targeted.   
Conclusions 
 The simplified laboratory diagnostics demonstrated improved specificity and 
feasibility of use in the remote areas in our surveillance study.  While V. cholerae was 
minimally present in the first year of surveillance, the outbreaks were detected early due to 
the application of our epidemiological and laboratory methodologies in the study area.  We 
found that while the outbreaks in Bourrha, Cameroon and Darak, Cameroon were from 
distinct clonal complexes, there was a genetic relationship among the genotypes suggesting 
that the strain mutated between the geographic areas.  The cholera RAT demonstrated the 
value of a risk factor weighting system to identify areas of heightened cholera risk for 
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Cholera has been recognized for its deadly dehydrating illness throughout recorded 
human history, with the first recorded pandemic occurring in 1817 throughout the Indian 
subcontinent (1, 2).  To date there have been seven cholera pandemics, most lasting 
between 5-20 years.  However, the most recent pandemic began in 1961 in Sulawesi, 
Indonesia and subsequently spread to Southeast and South Asia, the Middle East, Europe, 
reaching sub-Saharan Africa in the 1970’s and Latin America in 1991 (3).  The 7th 
pandemic continues to thrive today as cholera outbreaks are occurring around the world 
with increasing frequency and severity (4).  The strain responsible for the current pandemic 
is the El Tor biotype of V. cholerae serogroup 01, having gradually replaced the classical 
biotype of the first six pandemics and now has spread throughout most of the developing 
world (4, 5).   El Tor is known to persist longer in the environment and causes more 
asymptomatic cases which shed extensively into excrement, creating further spread of 
infection  (6).  These two characteristics of the El Tor biotype enable the pathogen to spread 
into new locations unnoticed and once the pathogen has found a new location it will likely 
persist and become a cholera endemic area.  This is one reason that the current epidemic 
continues still today (4).   Beginning in 1992, novel variants of O1 serogroup began to 
emerge with the first being O139 Bengal which spread rapidly throughout Bangladesh and 
into neighboring countries, displacing V. cholerae O1 El Tor (7).  While it was anticipated 
to start a new pandemic, V. cholerae O1 El Tor re-emerged in 1994.  V. cholerae O139 
continues to coexist with O1 El Tor, however, it is extremely rare and has not been reported 




variant or altered strains of El Tor strains producing classical cholera toxin (CT) have 
completely replaced the original 7th pandemic EL strain producing El Tor CT.  It is 
hypothesized that this altered strain is an evolutionary change in the El Tor biotype to create 
a new, more virulent and efficient El Tor Biotype (5, 9). 
 
1.2 Disease Burden  
Worldwide: 
While the numbers reported globally vary due to the fact that only around 1% of 
cholera cases are actually reported (10), it is estimated that cholera continues to infect 
millions of people every year resulting in over 100,000 deaths annually (4).  Under-
reporting is likely a result of lack of proper disease surveillance and a lack of adequate 
laboratory capacity especially in remote/rural areas, additional hindrances in reporting 
include fear of economic and social repercussions (11).  The most recently publicized 
outbreak occurred in Haiti in 2010, infecting ~ 500,000 people within one year and killing 
nearly 7,000 (12).  As a result of the devastating events in Haiti, much needed attention has 
shifted to addressing the needs for better strategies for the detection, prevention and 
treatment of cholera cases.  In their 2010 position paper on cholera vaccines, the WHO 
modified their recommendation stating that the WHO pre-qualified oral cholera vaccines 
should be used in conjunction with other prevention and control strategies in endemic and 
outbreak areas (6).  Due to the lack of adequate vaccine supply, the vaccine must be 
administered in a strategic manner to maximize protection of vulnerable people in both 





Disease Burden in South Asia 
Cholera is often referred to as “Asiatic Cholera”, as historically cholera is traced 
back to its presence in the Indian subcontinent.  A description of a  cholera-like disease is 
described in the Sushruta Samita, which is estimated to have been written between 400-
500BC (14), after which the earliest recorded records of its presence in India are recorded 
in 1769 (2).  In spite of records of cholera at this time, little information about the disease 
exists, and the first recorded cholera pandemic began in 1816, as the disease began to 
spread from India to China, the Philippines, Mauritius and Turkey, among other places (2). 
5 more pandemics continued through 1960, spreading globally to almost all continents; 
however, cholera did not persist in any of the new geographical areas as it did in the Ganges 
Delta where it became an endemic disease. The current and 7th pandemic strain has differed 
in that it has become endemic globally, particularly in south Asia and Africa (15), however, 
all seven distinct pandemics have spread from Asia to other countries. 
 
Disease Burden in Africa: 
Except for the 2010 cholera epidemic in Haiti, the area globally reporting the worst 
cholera epidemics is sub-Saharan Africa.  In 2007, the World Health Organization (WHO) 
Regional Committee for Africa officially recognized the resurgence of cholera in the 
African Region, and in 2010 a review of the situation in the African region found that the 
recurring cholera epidemics remained “alarming” (16).  The spread of the 7th pandemic 
strain of cholera reached sub-Saharan Africa in August 1970 with the first cases identified 
in Guinea.  The subsequent epidemic resulted in a reported over 150,000 cases and 20,000 




Cholera has maintained a consistently high case-fatality rate reporting thousands of deaths 
every year on the continent (18).   Unlike the classical waterborne disease, cholera in Africa 
spread not only through coastal areas but it also moved inland to savannahs, freshwater 
lakes and deserts which are not normally suspected to be conducive to vibrio survival (17).  
This may be due to transient refugees in overcrowded camps during the 1970’s and 1980’s; 
their migration along with other forms of trade and travel likely helped establish the 
endemic presence where it would not have been otherwise expected (17).   As stated above, 
issues with surveillance and reporting in Africa have also resulted in the likely 
underestimation of reported cases and deaths.  In the past decade, the number of countries 
reporting cholera has increased in sub-Saharan Africa, with more than 94% of the total 
global cholera cases reported in sub-Saharan Africa since 2001(18).  According to the 
WHO, only five countries have reported cholera outbreaks every year since 1990, all of 
which are in Africa: Burundi, the Democratic Republic of the Congo, Ghana, Tanzania, 
and Cameroon (19).   Alarmingly, recent developments show that  cholera epidemics in 
sub-Saharan Africa are not only becoming more frequent, but are larger in size and persist 
for longer durations of time.  For example, the 2008-2009 epidemic in Zimbabwe lasted 
for 11 months (8).   Factors warranting a more comprehensive, multi-faceted approach to 
prevent, detect and treat cholera include its increasing endemicity throughout Africa, the 
lack of adequate water and sanitation infrastructure, the lack of access to adequate 
healthcare, and the lack of access to education on life-saving treatments such as oral-
rehydration solution.     
 




The Republic of Cameroon has a population of approximately 20,000,000 people, 
with approximately 40% of the population under the age of 15 (20).  Cameroon is organized 
into 10 provinces, and further subdivided into 58 departments (21); the provinces have 
varied geographies.  This includes several climatic zones: two main types climatic regions 
are the Equatorial domain and the Tropical domain.  The Equatorial domain is broken down 
into the Guinea type, the Cameroon type, the maritime Cameroon type, and the montane 
Cameroon type.  The Tropical domain is broken down into the Sudan or humid climate 
zone and the Sahel climate zone.  The Far North of Cameroon (FNC), in the Sahel climate 
zone, experiences a very short rainy season of approximately four months; while the 
maritime zone includes Debundscha which is the second rainiest place in the world; in 
contrast to the Guinea type in the Southern Plateau of the country where there are four 
seasons, two rainy and two dry (22).  Per the Ministry of Health of Cameroon, there are 10 
health regions, with 181 functional health districts as of 2012 (J.Ateudjieu – personal 
communication).  Major infectious diseases affecting the region include malaria, yellow 
fever, HIV/AIDS as well as food and waterborne diseases as a result of bacteria or protozoa 
(20). Only about half of the rural population of Cameroon has access to improved drinking 
water (47%) (23), and less than half have electricity (47%) (20).  Cholera cases are 
increasingly abundant in Cameroon, specifically in the Far North Region with 9 outbreaks 
in the region since 1996, with the cholera outbreak in 2010 being the most serious outbreak 
in decades with almost 10,000 cases and 599 deaths (a 6.37% CFR) reported just 238 days 
after the outbreak began (24).  It is likely that these numbers are an underestimate of the 




laboratory diagnostic capabilities hinder the ability to adequately estimate the true disease 
burden (Figure 1.1).   
The Far North of Cameroon (FNC) is part of the Lake Chad Basin region of Africa.  
The Basin region includes parts of Chad, Nigeria, Niger and Cameroon.  The center of the 
Basin is a shallow freshwater lake that is 22,000km2.   The lake is surrounded by wetlands 
which are affected by the seasonal variation in the hydrology of the rivers that flow into 
the Lake Chad Basin (16).  This rural area is also unique in that in spite of its isolation it is 
a crossroads for communication among the bordering countries and thus is a type of center 
for commercial activities.  Additionally, as a result of the seasonal variation in water flow, 
populations are often displaced.  Food security, water availability, and access to health care 
are the poorest in the country in the FNC, likely further exacerbated by the extreme climate 
situation (25).  These characteristics, particularly the economic activities, demographic 
changes, and the additional lack of access to protected water sources make this region 
vulnerable to cholera outbreaks in which the attack rates are high and case fatality rates 
(CFRs) are above 5% (16).    
The region was not spared when cholera arrived in Africa in 1971.  Outbreaks have 
continued to affect the region today due to the same demographic movement/displacements, 
as well as lack of access to medical care and lack of access to safe water.  Then in 1991 
there was an unusual intensity in the cholera outbreak in the Lake Chad Basin with 80,600 
cases and 9800 deaths reported among the four countries.  The spread of the epidemic, 
similar to the first outbreak of cholera in 1971, followed trade routes by both land and water 
(16).   In 2010, the Lake Chad Basin countries suffered one of the largest epidemics in the 




“L’Extreme Nord” in French, has had consistent outbreaks in recent years.  In 2009, of the 
814 cases reported in the one outbreak, there were 39 deaths with 395 cases presenting in 
the FNC and 419 in the North of Cameroon (case fatality rate 11.07%).  A second outbreak 
in 2009 reported 407 cases of cholera and 65 deaths in the FNC (case fatality rate 16%).  
In 2010, the first outbreaks occurred in Makary and Mada at the start of the rainy season 
in May.  By late November 2010, a total of 9,712 cases and 610 deaths (case fatality rate 
28%) were registered in the FNC, the North, the Littoral Region (coastline) and the Centre 
(Figure 1.2) (26). 
 
Disease Burden in Kenya: 
The Republic of Kenya has a population of over 45 million people, with over 43% 
of the population 15 years of age and younger (27). It is organized into 8 provinces, and 69 
districts (28). Kenya’s geography is varied including coastal, lake, highland, (29) and 80% 
of the country’s land area is semi-arid or arid. The country is comprised of two regions: 
the lowlands including the coastal region and the highlands, which extends on both sides 
of the Great Rift Valley.  The four seasons in Kenya include a dry season from January to 
March, a rainy season from March to May, a dry season from May to October and a rainy 
season from October to December (27).  According to the 2009 census, while ~90% of 
urban households have access to improved water sources, only approximately 50% of rural 
households have such access.  In addition the type of improved water source greatly differs 
with urban households predominantly having piped water into the dwelling while rural 
households primarily have access to dug wells as an improved water source.  Access to 




only 30% of urban and 20% of rural households have access to an improved toilet facility 
(27).  Per UNICEF’s 2012 Update on the Progress of Drinking Water and Sanitation, 
Kenya is among ten countries with the largest population without access to an improved 
drinking water source (30). 
Cholera first appeared in Kenya in 1971, with fifteen distinct outbreaks from 1971 
through 2010.  These outbreaks have ranged in size as well as morbidity and mortality, but 
in comparison to Case Fatality Rates (CFRs) reported in Asia, the CFRs in Kenya have 
been markedly higher and cholera is a significant cause of death from diarrhea (31).  
According to the Weekly Epidemiological Reports (WER) from the WHO, the cholera 
outbreaks in Kenya have been increasing in size as well as mortality rates since 2007 (32).  
Several regions of the country are reportedly more prone to cholera outbreaks, including 
the Nyanza province which reported outbreaks in 1997-1999 and again from 2007-2010, 
the refugee camps in urban Nairobi, the Turkana province and the North East province 
where large refugee camps exist (29).  Shikanga et al reported on the 2008 outbreaks in 
Nyanza during a period of civil unrest in Kenya.  The study reported significant 
underreporting of cases and deaths; through active-case finding they found a 200% increase 
in the number of deaths and a 37% increase in the number of cases reported (33). 
 




The history of cholera is often tied to John Snow’s historic epidemiological search 
to demonstrate the link between contaminated water and infection in England in 1854, and 




important to remember that this is not the sole means of transmission as V. cholerae can 
also be transmitted via contaminated food, particularly inadequately cooked seafood.  
Additionally, cholera can persist in leftover foods such as rice and millet for days (17). 
Direct person-to-person transmission is rare due to the large quantity of V. cholerae that is 
required to result in disease (8).    
 In areas where cholera is endemic, it is known to display seasonality with one or 
two annual peaks (34).  However, the annual rates in endemic areas often vary widely, 
likely due to environmental and climate variation.  It remains unclear as to what is the 
determining factor in the seasonal appearance of epidemic cholera; it has been suggested 
that during inter-epidemic periods that toxigenic V. cholerae persist in association with 
aquatic organisms until an environmental trigger results in the multiplication and 
proliferation of the dormant bacteria (15). 
Humans are the only known vertebrate hosts of V. cholerae, and of the 25% of 
persons infected who develop symptoms, only 10-20% will develop severe disease after an 
incubation period of 2 hours to 5 days post-infection.  The remaining 75% of persons 
infected with V. cholerae who do not become symptomatic may still shed the bacteria, 
potentially exposing other people(35)..   Infection severity is dependent on local intestinal 
immunity, the size of the inoculum, the patients gastric-acid barrier, and the patient’s blood 
group (15).   
1.3.2 Clinical Presentation: 
 
Cholera is identified often by the rapid onset of acute watery diarrhea and vomiting.  
The disease can progress rapidly from the first watery stool to shock in as little as 4-12 




stool and clear, watery vomit.  The rate of the loss of fluid plays a role in risk of death; if 
extremely rapid the patient may die within a few hours of onset.  Without treatment the 
case-fatality rate (CFR) for severe diarrhea can be as great as 50%.  However, if fluids are 
given promptly, the case fatality rate can be reduced to as little as <1% (34). 
 Treatment options depend on the severity of cholera infection, utilizing fluids 
comprised of a similar electrolyte composition to those that have been purged.  Severe 
cases require intravenous fluid followed by oral rehydration solution (ORS) in order to 
compensate quickly for the volume of fluid that has already been lost.  Severe cases should 
also receive antibiotics (doxycycline) for 1-3 days to shorten the illness and reduce diarrhea.  
For patients of lesser degrees of dehydration, ORS provides sufficient rehydration.  




Cholera’s acute diarrheal infection is the result of direct fecal-oral contamination 
or ingestion of contaminated food or water with Vibrio cholerae.  V. cholerae are 
facultatively anaerobic, asporogenous, motile, gram-negative rods ranging from 1.4 to 
2.6µm in length (36).  Unlike most bacteria, V. cholerae has its genome divided into two 
circular chromosomes, a discovery made in 1998 by Trucksis et al (37).  Chromosome I is 
the larger chromosome with 2,961,146 base pairs, containing crucial genes for essential 
cell functions and pathogenicity.  V. cholerae requires two regulated factors for full 
virulence: cholera toxin (CT) and toxin-coregulated pilus (TCP) (38).    The production of 
the toxin CT, encoded by the ctxAB gene, is located within the integrated genome of a 




cell is the surface organelle TCP which is required for intestinal colonization.  All strains 
capable of causing cholera must also possess a regulatory protein, ToxR, which co-
regulates the expression of CT and TCP (40).  Therefore, there are two regions of the V. 
cholerae chromosome I in which virulence factors are clustered: the CTX element and the 
TCP pathogenecity island (VPI), which is composed of the TCP-accessory colonization 
factor (ACF) gene cluster (39).   Research suggests that the horizontal transfer of these 
gene clusters may be responsible for the origination of new pathogenic V. cholerae strains. 
The ctxɸ plays a critical role in this transfer of genes from one V. cholerae strain to another.  
For example, the transformation of O1 El Tor strains to O139 occurred as a result of one 
or more horizontal gene a transfer event in which there was a deletion and replacement of 
gene clusters encoding lipopolysaccharide O-side chain synthesis enzymes (41). 
The smaller chromosome II with 1,072,315 base pairs is plasmid-like but due to its 
size and functions is considered a chromosome that may have once been a megaplasmid 
captured by a Vibrio species.  This chromosome encodes potential toxins including hap 
and hlya virulence factors (Figure 1.3) (39). 
The ability of cholera to reach and subsequently colonize the small intestine of 
humans and produce CT is a complex process.  CT consists of five binding (B) subunits 
and one active (A) subunit (15).  The B subunits bind to GM1 ganglioside receptors in the 
small intestine mucosa, the A subunit is then transported into the cell where it activates 
adenylate cyclase, leading to an increase in cyclic AMP (42).    The resulting ion fluxes 
lead to in an increase in chloride secretion and a reduction to zero absorption of sodium.  
The end result is discharge of fluid into the small intestine that exceeds the normal 




rich resulting in low blood pressure and shock.  Additionally, the fluid contains high 
concentrations of cholera vibrios that are highly infectious and can further contaminate 
environmental sources (15). 
The organism is classified by biochemical tests for which it ferments glucose, 
sucrose and mannitol and is positive in the lysine and ornithine decarboxylase tests.  It is 
then further subdivided into serogroups based on the polysaccharides of the somatic O 
antigen, of which there are over 200 serogroups (15).  However, only 01 and 0139 have 
been associated with epidemic disease (43).  Strains that test positive for V. cholerae but 
do not agglutinate with O1 or O139 antisera are referred to as non-O1/non O139 V. 
cholerae; while not involved in epidemics these strains can still be pathogenic (6).   
Serogroup 01 can be further divided into two biotypes, El Tor and classical; both of which 
can be further classified into two serotypes: Ogawa and Inaba.  Ogawa strains produce the 
A and B antigens and a small amount of C antigen, which can be differentiated from Inaba 
by biotype specific genes as it only produces A and C antigens.  An additional serotype 
known as Hikojima produces both specific antigens but is very rare (Figure 1.4) (15, 44). 
Identification of V. cholerae O1 or O139 is performed by culture of fecal specimens 
on thiosulphate citrate bile salts sucrose (TCBS) agar as it inhibits the growth of most 
normal flora while allowing the growth of vibrios.  Alternatively, a fecal specimen may be 
incubated in alkaline peptone water, as it preferentially supports the growth of vibrios, for 
6-12 before inoculating the TCBS plate.  V. cholerae produces smooth yellow colonies on 
TCBS agar that have slightly raised centers, these colonies can be selected and tested for 
presumptive identification if they are oxidase-positive and agglutinate with either O1 or 




In the absence of laboratory capabilities, rapid diagnostic tests (RDTs) have been 
developed to diagnose toxigenic V. cholerae in a field setting.  Based on lateral flow 
immunochromatography, the RDT tests fecal specimens for a qualitative response to 
monoclonal antibodies specific for V. cholerae O1 or O139 lipopolysaccharide (LPS). As 
depicted in Figure 5, the dipstick works similarly to a pregnancy test.  There are two 
antibodies present on the dipstick: one is the colloidal gold-labeled detection antibody and 
the second is the capture antibody (anti V. cholerae O1 and O139 antibody as there are 
separate identification bands for each).  When the dipstick is placed into the test tube 
containing the fecal sample, there is a binding reaction forming a complex with the analyte 
in the liquid specimen.  This complex moves forward continuously on the dipstick until it 
is eventually captured by the antibody(s) on the surface of the nitrocellulose membrane.  
The nitrocellulose membrane provides a pore to allow the liquid-solid interface necessary 
for antibody-antigen binding (45).   After ten minutes, and within 15-20 minutes, the results 
can be read in which there is a color signal representing a positive for V. cholerae O1, 
O139, both or if negative, no color signal other than the control band is visible.  There is 
also a control band in which an antibody specific to the detection antibody is used to 
demonstrate that the dipstick functioned properly.  This band should be visible after all 




While traditionally accepted that cholera spreads via fecal contamination of water 
or food, recent studies have demonstrated that V. cholerae including pathogenic O1 and 




association with plankton independently of infected human beings (15).    However, Non-
O1 and non-O139 are more commonly isolated from the environment; V. cholerae O1 
isolated outside of epidemic areas have mostly been CT negative.  The life cycle of V. 
cholerae consists of two distinct phases illustrated in Figure 1; during the environmental 
phase, vibrios can be found as free swimming or attached to plant surfaces.  However, in 
the 2nd/human phase genetic factors for colonization of the mammalian gut are necessary.  
As previously described, these major pathogenic genes lie in several clustered regions of 
the V. cholerae chromosome.   This suggests the theory that the natural marine vibrios 
adapt to the intestinal environment through horizontal acquisition of the virulence genes 
during phases of infection (40).  This evolution to pathogenicity would require first that 
strains acquire the VPI and secondly, the now TCP-positive strains are infected with and 
lysogenized by CTXɸ (Figure 1.6).  
The term “hyperinfectivity” is used to describe the fact that organisms from one 
infected person become more infectious as they are passed to the second/subsequent 
infected individuals during a cholera outbreak.  However, it is difficult to isolate vibrios 
from suspected environmental or water sources; additionally, clinical isolates are 
genetically similar and difficult to differentiate among pathogenic V. cholerae strains (47).  
There are many current methods for differentiating strains including: rRNA restriction 
fragment length polymorphism (ribotyping), pulse-field gel electrophoresis (PFGE), and 
multilocus sequence typing (MLST), among others.  However, recent research has revealed 
limitations in many of these methods as most CT positive O1 and O139 isolates are 




Ribotyping involves the use of E. coli rRNA gene probes to compare restriction 
fragment length polymorphisms of conserved rRNA genes, including 16S and 23S, in 
different strains to determine if different patterns are present (48).  However, the 
application of this methodology to the study of V. cholerae has identified approximately 
30 ribotypes, of which only a few are common in clinical isolates.  Additionally, the 
ribotypes evolve slowly as isolates of a specific V. cholerae serotype over a period of many 
years in a single area belong to a single ribotype (47).       
PFGE is performed by embedding organisms in agarose, lysing the organisms and 
then using restriction endonuclease digestion to cleave DNA fragments.  The DNA 
fragments are run on an agarose gel to resolve the restriction fragments into discrete bands 
for comparison with other isolate restriction patterns to determine relatedness of the 
isolates (49).   PFGE has been shown to be more sensitive in V. cholerae subtyping than 
ribotyping (50, 51), however, PFGE types change slowly and are beneficial primarily for 
distinguishing between pandemic strains (47). 
MLST, first described in 1998, shifts towards a more sequence-based approach as 
a single gene may not be useful in determining genetic relatedness of isolates.  MLST is 
used to characterize isolates by the nucleotide sequence of specific housekeeping genes.  
In comparison to PFGE which examines variations among specific restriction sites; MLST 
reveals all genetic variations within an amplified gene fragment (52).    However, this 
method has been useful mainly for characterizing relationships among non-toxigenic 
strains as well as for linking regional outbreaks with the responsible pandemic strain (47). 
To distinguish pathogenic O1 from O139 strains for epidemiological purposes, 




method that enables strains to be distinguished within a species in order to monitor 
epidemics as well as routes of contamination is Multi-locus variable-number tandem-repeat 
(VNTR) analysis (MLVA) (53).  This methodology is used to assess variable-number 
tandem repeats or simple sequence repeats (SSR) are known as a class of short DNA 
sequence motifs that are tandemly repeated at a specific locus.  The method uses the 
number of repeats at each different locus as a fingerprint for distinguishing among isolates 
(47).  As demonstrated in studies by Noller et al, E. coli O157 isolates that were 
indistinguishable by MLST could be distinguished to some extent by PFGE but ultimately, 
MLVA was able to distinguish isolates that had the same PFGE type (54). 
SSRs occur due to the fact that short arrays of repeat units may engage in modified 
or erroneous base-pairing when being copied by DNA polymerase.  As a result, the 
polymerase introduces or deletes individual repeat units.  Ultimately, the frequency of these 
variations depends on the DNA repair system, and the repeat variability affects genome 
functioning (55).  The random modification of gene coding may be biologically 
advantageous for microorganisms; important epidemiological questions can be assessed 
through determination of these changes and assessing relatedness among isolates.  Recently, 
17 VNTR loci were shown to differentiate V. cholerae strains that were indistinguishable 
by PFGE (53).  Subsequently, a study of a second group of VNTR loci demonstrated that 
environmental and clinical isolates from distinct Bangladeshi villages could be 
distinguished utilizing five VNTR loci (56). 
 





1.4.1 Vaccine History: 
 
 The history of cholera vaccines dates back to the 1800’s beginning with the 
discovery by Louis Pasteur that attenuated organisms could be used for immunizing 
domestic animals against infectious diseases, one of these diseases for which he developed 
a method of attenuation was for chicken cholera in 1880.  In 1885, a Spanish physician, 
Jaime Ferran y Clua, was the first to immunize humans against any bacterial disease, 
vaccinating at least 30,000 Spaniards against cholera (57).  Unfortunately, Ferran’s work 
was disregarded at the time as being without scientific merit due to his unwillingness to 
detail his methods of attenuation.  Subsequently, while working at the Pasteur Institute, 
Russian scientist Waldemar Haffkine vaccinated himself and 3 colleagues with two 
separate live cholera vaccines.  The first attenuated vaccine was followed 6 days later by a 
second vaccine with enhanced virulence, as Haffkine’s hypothesis was that the second 
enhanced vaccine would produce greater immunity.   Haffkine continued to work out the 
best method of vaccination through trials in India and Bangladesh.  While Ferran is 
recognized as the first to have inoculated humans, Haffkine is considered the creator of the 
controlled human testing of an acceptable cholera vaccine (57).  Injected, or parenteral, 
attenuated cholera vaccines were used until the 1970’s at which time a study in Bangladesh 
showed that the vaccines only conferred approximately 50% protection to the recipient for 
a period of less than six months post-vaccination (58). 
 Attention in the cholera vaccine field shifted toward oral vaccines with the 
understanding that immunity from cholera results mainly from mucosally secreted 
intestinal antibodies.  Additionally, oral vaccines are easier to administer, more acceptable 




types of oral cholera vaccines: killed whole cell (WC) vaccines and genetically attenuated 
live vaccines (11).  Two of the killed whole cell vaccines are WHO qualified as of 2011: 
the first internationally licensed was the killed WC Vaccine with CT B Subunit (Dukoral) 
and the killed WC vaccine without the CT B subunit (Shanchol) (59).   
1.4.2 Current Vaccines 
 
Dukoral was developed in Sweden and first licensed in 1991; currently it is licensed 
in more than 60 countries but it is primarily used as a traveler’s vaccine due to its high 
price (11)($5.25 per dose to the private sector) (60).  The vaccine consists of a mixture 
either heat or formalin killed WC El Tor and Classical V. cholerae O1 biotypes 
representing both the Ogawa and Inaba serotypes with the addition of the B subunit of the 
cholera toxin.  The vaccine must be given with a bicarbonate buffer in order to neutralize 
gastric acid and prevent the CT B-subunit from being destroyed.  The vaccine works 
through the induction of antibodies against the bacterial components of the vaccine as well 
as the CT B.  The antibodies produced against the bacterial components of the vaccine 
work by preventing V. cholerae from binding to the intestinal wall; ultimately impeding 
colonization of the bacteria.  The antibodies to CT B prevent the cholera toxin from binding 
to the intestinal mucosal surface which prevents the toxin-induced diarrheal symptoms (61).  
The vaccine is licensed for use in persons 2 years of age and older; with persons 6 years 
and older requiring 2 doses given at least 7 days apart (but less than 6 weeks apart) and 
those between 2 and 5 years of age requiring 3 doses at least 7 days apart (but less than 6 
weeks apart) (11).   A randomized controlled trail in Bangladesh demonstrated a vaccine 
efficacy of 85% for 4-6 months following vaccination, with an indirect protective effect of 




demonstrated more than 80% protection in the first year following vaccination in non-
pregnant people greater than 2 years of age.  This study also demonstrates that the vaccine 
is protective against the new variant El Tor expressing classical CT (63).  Finally, since CT 
B is both structurally and functionally similar to heat-labile toxin of enterotoxigenic 
Eschericia coli (ETEC), there is cross protection against ETEC infections with this vaccine.  
This was demonstrated in a study in Matlab in which Dukoral provided short term 
protection against ETEC infection (59). 
Shanchol is the killed WC vaccine without the CT B-subunit, which is the 
reformulated mORC-VAX by Shantha Biotechnics in India, where the national regulatory 
authority has WHO approval.  The original 01 serogroup killed WC vaccine without CT 
B-subunit was developed and manufactured in Vietnam (mORC-VAX) in the 1980’s and 
was subsequently made into a bivalent (O1 and O139) formulation (59).  This low cost 
vaccine, ($0.75 per dose to the public sector) does not require oral buffer during 
administration since it does not contain the CT B-subunit.    However, mORC-VAX had 
limitations making its prequalification by WHO unlikely including: production methods 
that were not adaptable to Good Manufacturing Practices (GMP), lack of compliance in 
standardization tests with recommendations and the vaccine was found to contain residual 
CT (60).   Thus, a new bivalent (O1 and O139 serotypes) vaccine was created (Shanchol) 
using a heat-killed classical Inaba strain and a formalin-killed classical Ogawa strain.  
Similar to mORC-VAX, Shanchol requires no oral buffer for administration, is approved 
for persons greater than 1 year of age, requires 2 doses at two-week intervals, and is 
significantly cheaper in price than Dukoral ($1.85 per dose to the public sector) (60).   




demonstrated in more than 67,000 people that the vaccine was 66% efficacious during a 3 
year period of follow up, and more recently shown to have a cumulative protective efficacy 
of 65% after five years (64).  It subsequently received WHO prequalification in 2011 (59). 
CVD 103-HgR (Orochol or Mutachol) is a genetically engineered, live-attenuated 
V. cholerae O1 Inaba strain in which the gene for the cholera toxin A subunit was deleted 
and a gene for mercury resistance was inserted (60).  A single dose of the vaccine has been 
shown to be 95% protection against classical strains and 65% protection against El Tor 
Strains (11).   However, a phase III efficacy trail in Indonesia reported no protection 
detectable against cholera in the four years of follow-up to a single dose regimen.  As a 
result, the vaccine has never been licensed for use in settings of endemicity (65).  Its safety 
profile and protection did lead to its licensure as a traveler’s vaccine in Switzerland in 1993 
(11) but it is not currently being marketed.  There are plans to re-introduce the vaccine by 
another company (PaxVax) soon (66).   
Several other live OCV candidates are currently being developed, including Peru-
15, a genetically engineered V. cholerae O1 El Tor Inaba strain isolated in Peru.  Peru-15 
is the most advanced OCV candidate as it was tested in over 500 children and adults and 
shown to be safe and immunogenic in both endemic (Bangladesh) and non-endemic (US) 
populations (59). 
 
1.5 Prevention Strategies and Challenges 
As evidenced by recent coverage of the cholera outbreaks in Cameroon, South 
Sudan, Guinea, and other countries; the disease persists as a major problem in many 




cholera surveillance remains a vital component for determining patterns of cholera 
incidence and prevalence in different areas of the world.  However, as previously noted, it 
is well documented by the WHO and others that the number of globally reported cholera 
cases is significantly underestimated. From 2007-2010, the annual global figures which 
were reported to the WHO claimed that there were between 178,000 – 237,000 cases of 
cholera, with 4,000 – 6,300 deaths (68).  However, it is estimated that these figures only 
represent 5-10% of the actual number of cases occurring annually worldwide (69), with the 
actual burden of disease estimated to be between 3 – 5 million cases annually, with 100,000 
– 130,000 deaths per year (59).  The reasons previously discussed contribute to 
underreporting, such as fear of economic and societal consequences and political 
disincentives.  However, a significant influence to the under-reporting is predominantly 
due to surveillance difficulties, owing both to lack of proper epidemiological surveillance 
systems as well as to a lack of adequate laboratory facilities (69).   
 Surveillance systems and the data that they produce are vital to determining the 
pattern of disease occurrence in a country or region of interest.  This data is necessary to 
facilitate disease control efforts, and in situations where vaccines are available, can be 
instrumental in local and governmental decisions about vaccine introduction (70).  
Surveillance data can be collected using various methodologies.  Population-based 
surveillance identifies ~100% of new cases of the targeted disease in a defined population.  
This provides information that can be used to calculate the disease incidence rate in the 
defined population.  Unfortunately, population surveillance is often too costly and 
logistically time-consuming.  An alternate strategy is to utilize sentinel surveillance 




selected number of facilities.  This method requires fewer resources and is generally less-
costly than population based surveillance.  While there are limitations in estimating 
incidence rates, the increased feasibility of sentinel surveillance as compared to population-
based surveillance has led the WHO to recommend its use for monitoring the effect of 
newly implemented vaccines (71). 
In remote areas of developing countries sentinel surveillance may still prove to be 
too costly and too resource intensive for the limited district and/or regional health budgets.  
In 2003, a study was published in which a sampling system was utilized to survey for 
cholera in 4 distinct geographic locations in Bangladesh.  The surveillance was conducted 
in a local hospital in each of the 4 sites; a physician collected clinical data and specimens 
from patients presenting with acute water diarrhea during a 3 day period every fifteen days 
(72).    This sampling methodology was implemented for its sustainability in resource-
constrained environments.  Experts on epidemiological surveillance have noted that it is 
not essential to have complete counts of diseases to implement disease-control efforts.  
Even sporadic reporting of cases can reveal unusual disease occurrence, stimulating 
investigations and disease-control activities (73). 
The surveillance data recording and reporting the disease burden of cholera around 
the globe has likely hindered the consideration of OCV’s by policy makers both at the 
international level by agencies such as the WHO advisory group, as well as decision makers 
in high risk countries.  These factors have contributed to the lack of demand for OCV by 
manufacturers; ultimately resulting in a lack of available vaccine supply.  While measuring 
disease burden is difficult with limited surveillance data; it is even more difficult to 




awareness of the impact of the disease.  In 2004, a standardized rapid assessment tool 
(RAT) was developed by the WHO to estimate the incidence of Haemophilus influenzae B 
(Hib) meningitis and Hib pneumonia.  This tool illustrated that limited retrospective data 
on local rates of Hib disease could provide disease burden rates similar to those obtained 
from population-based studies in the same regions.  This tool provides an inexpensive 
means of using locally obtained data while engaging health care workers and government 
officials to evaluate existing local surveillance data and to assess rates of disease (74).   The 
framework established for assessment of Hib disease burden can be useful in conducting 
the same or similar assessment for cholera disease burden in high risk countries in order to 
highlight the need for disease-control efforts and engage policy makers in discussion on 




















Several large field trials have been conducted to demonstrate safety and 
immunogenicity of both Dukoral and Shanchol (64, 75-78).  A cluster-randomized phase 




demonstrating vaccine efficacy of more than 65% after five years (64)  Cholera 
intervention campaigns including OCV, training in Water, Sanitation and Hygiene (WaSH) 
and knowledge attitude and practice (KAP) about cholera were implemented in refugee 
camps in Tak Province, Thailand (78) and in urban (Mirpur and Dhaka)  and rural 
(Keraniganj)  settings of Bangladesh (79) , reactive vaccination in Guinea (80) In 2012, 
several additional vaccination implementation campaigns were conducted including a 
reactive vaccine campaign 2 years into the epidemic in Haiti combined with an assessment 
of feasibility of vaccine delivery initiated in Haiti in which the delivery of the vaccine 
improved the baseline knowledge and essential health practices necessary for cholera 
control (81). In 2012 another reactive campaign was conducted in Boffa and Fore’cariah, 
Guinea.  Following the report of over 147 cases and 13 deaths between February and March 
of 2012, the Ministry of Health (MoH) of Guinea, with the support of Médecins Sans 
Frontières (MSF) implemented the first reactive OCV campaign in Africa (82).  Despite a 
short time interval for implementation the campaign was successful with a high degree of 
acceptance.by the population and high vaccination coverage (80). A re-analysis of data 
collected during the field trial of Dukoral in Bangladesh demonstrated herd protection in 
the unvaccinated persons in the community, suggesting that high levels of vaccine coverage 
in a community can lead to increasing levels of indirect protection (herd protection)  (62).  
These findings were supported in efficacy studies conducted following a mass vaccination 
campaign in Zanzibar6, further highlighting the importance of herd protection benefits 
when considering vaccine implementation.  In conjunction with such clear evidence 




2010 supporting the use of the 2 WHO approved OCV’s  in conjunction with other 
interventions for cholera’s prevention and control in cholera affected areas (6). 
While the evidence has been successfully presented for the implementation of OCV, 
there have been considerable obstacles to its implementation.  These include the need for 
a cold chain for the vaccine, the large volume needed for the Dukoral vaccine, the multi-
dose requirement within a short timeframe, the vaccine is not 100% efficacious, concern 
that its use might detract from other important interventions such as water and sanitation 
hygiene (WASH) efforts, and as seen in Haiti, concerns that it might interfere with other 
national vaccination efforts.  These obstacles can be addressed through logistical planning 
as well as working well with other agencies such as WASH efforts to utilize OCV as a tool 
to complement water and sanitation activities to create a comprehensive approach.  
Additionally, the individual vaccine efficacy does not have to be extremely high if the 
vaccine also has demonstrated herd immunity (59); however, the obstacle that continues to 
heavily impede progress in vaccine implementation is the shortage of supply of vaccine 
(83).  As a result of the current situation, it is necessary to improve surveillance in high 
risk areas in order to apply targeted vaccination strategies and optimize the available 
number of vaccines.  The overall goal of the “Delivering Oral Cholera Vaccine” (DOVE) 
project funded by the Bill and Melinda Gates Foundation is to facilitate and focus the 
delivery of oral Cholera vaccine (OCV) in high burden countries.  Unfortunately, there is 
currently a very poor understanding of both disease patterns and disease risks in most 
endemic countries, and few Ministries of Health in these affected countries are considering 




obtaining the vaccine, and logistical issues surrounding the distribution of the vaccine, 
among other obstacles.   
The Far North of Cameroon is an area of interest for understanding cholera 
epidemiology in sub-Saharan Africa as well as in developing targeted approaches towards 
vaccination.  As a result of repeated outbreaks with notably high case fatality rates (CFRs) 
since cholera first appeared on the African continent, the Lake Chad Basin is considered a 
“hot spot” of cholera disease.  Unlike Asian countries such as Bangladesh that are known 
to be cholera endemic as a result of monsoons and seasonal flooding, this area of sub-
Saharan Africa has entirely different environmental and climatic issues that may suggest a 
different set of risk factors to people living in the Lake Chad Basin.  As a sub-study to the 
DOVE project, the “Sustainable Cholera Surveillance for Cameroon” study will be 
conducting surveillance in the Far North region of Cameroon for the next four years.  The 
objective of this surveillance effort is to evaluate the use of low-cost and sustainable 
epidemiological and laboratory methods in remote and rural field settings.  We will work 
within this area to apply efficient epidemiologic and laboratory tests to facilitate the 
understanding of disease transmission in this area and work to provide tools for Cameroon 
and other similarly affected countries to rapidly assess their cholera disease burden and 
options for cholera intervention implementation, particularly the use of OCV. 
Infectious disease burden data is often minimally available or non-existent in 
developing countries.  Cholera disease burden data is similarly absent due to lack of 
surveillance in endemic areas as well as a result of fear of economic repercussions from 
reporting outbreaks (84).  The African continent has the most reported cholera cases.  As 




disease burden will be vital in facilitating decisions by the Ministry of Health.  The Risk 
Assessment Tool (RAT) will aid endemic countries such as Kenya in decisions regarding 
allocation of resources and implementation of intervention strategies, particularly targeted 
OCV campaigns. 
  
1.7 Overall Goals and Specific Aims 
 
1.7.1 Overall Goal of the Study 
 
 The overall goal of this dissertation was to assess sustainable and efficient tools for 
the epidemiological and laboratory surveillance of V. cholerae in low resource settings.  In 
a remote area in the Far North of Cameroon, the goals were to evaluate novel 
epidemiological and laboratory surveillance tools for the sustainability of routine 
surveillance and the characterization of disease burden.  In the endemic country of Kenya, 
the goal was to evaluate a rapid risk assessment tool that can provide disease burden 
information through the use of adjusted incidence and death rates with supplemental risk 
factor weighting that will highlight areas of high-risk for cholera intervention campaigns 
utilizing temporal, geographic and demographic factors from historical data.   
 
Specific Aim 1 
 To evaluate the implementation of modified sentinel surveillance using low-cost 
and rapid lab diagnostics in a low-resource and remote setting for concurrent 
environmental and clinical surveillance in an effort to understand cholera transmission 







Specific Aim 2 
 To determine the temporal and geographic genetic relationship between 
environmental specimens and clinical specimens isolated from persons and water sources 
in the far North region of Cameroon. 
 
Specific Aim 3 
To conduct a review of historical cholera surveillance data to determine the burden 
of disease of Cholera in Kenya while evaluating a rapid risk assessment tool; identifying 
















Figure 1.1: Cameroon (85) 








































Figure 1.3: “Image of two of the circular chromosomes found within Vibrio cholerae”. 
The image shows different sections of the chromosome that aid in toxicity. Each 




















































Figure 1.5: Crystal VC dipstick: Components and Schematic Diagram 
(a) Cross-section of the Crystal VC dipstick showing its assembled components. (b) 
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Biological Confirmation of the presence of Vibrio cholerae in both stool and water samples 
is often constrained due to resource and labor intensive gold-standards methods.  To 
develop low cost, simple and sustainable surveillance techniques, we modified previously 
published specimen sampling and enrichment techniques and applied the use of modified 
dipstick testing in conjunction with the use of filter paper for specimen preservation during 
epidemiological and environmental surveillance in the far North of Cameroon from August 
2013 – October 2014.  This methods allows for increased specificity and rapid diagnosis 
in a field setting, simplified DNA storage for PCR analysis of specimens, reduced need for 
reagent-intensive microbiological testing, elimination of cold-chain storage, and simplified 
transfer to reference laboratories. 
Methods 
Clinical and environmental surveillance was conducted in 7 health districts in the far North 
of Cameroon between August 2013 and October 2014.  The Clinical specimens were 
screened for V. cholerae 01 and 0139 using an enhanced dipstick method  in which 
specimens are tested Crystal VC dipstick after 6h of enrichment in APW broth.  The 
enriched stool sample is also preserved on filter paper for molecular processing.  
Environmental specimen are filtered through medical gauze and then incubated in a 50mL 
conical tube for 24 hours (range 22-26hours) at room temperature. After incubation, the 
enriched specimen is tested with Crystal VC dipsticks for Vibrio cholerae 01 and 0139.  
The enriched specimen is also preserved on filter paper.  Filter paper specimens are first 




a 2% Chelex-100 solution, incubated at 100°C for 8 minutes, and centrifuge to remove 
supernatant and store at -20°C.  DNA samples are tested using multiplex PCR for Vibrio 
spp. Including Vibrio cholerae, Vibrio vulnificus and Vibrio parahemolyticus.  Those 
positive for Vibrio cholerae were further tested differentiate toxigenic and non-toxigenic 
V. cholerae; and to differentiate serogroups 01 and 0139.   
Results 
949 patients were enrolled in the study among all 7 study sites, of which 28 were V. 
cholerae 01 positive and 2 were V. cholerae non01 positive.  Cholera was not detected in 
any of the study surveillance facilities until October 2014 when an outbreak was detected 
in Darak and Blangoua Health Facilities. Of the 28 patients enrolled in the study with 
clinically confirmed cholera and two additional non01 Cholera patients, nearly 40% (11) 
were children under 5 years of age, and nearly 75% were men.  The modified dipstick 
methodology demonstrated increased sensitivity (99.8%). 1,012 water samples were 
obtained from the 45 environmental sites surrounding the 7 Health Facilities, of which 244 
were V. cholerae non-01 positive and 0 where V. cholerae 01 positive.  An environmental 
reservoir for cholera was not identified, however, there was a significantly increased risk 
of vibrio cholerae detection near Naga and Darak Health facilities. 
Conclusions 
Simplified laboratory and epidemiological methodologies can improve the feasibility of 
cholera surveillance in rural and resource constrained areas.  The application of basic 
technologies such as the modified dipstick, the use of simplified gauze filtration for 
environmental sample collection, and the use filter paper for sample preservation enabled 




false positive results.  The first year of clinical and environmental surveillance did not 
identify a reservoir for V. cholerae in the Far North of Cameroon; however, the simplified 














































Annually only 1% or 100,000 of the estimated cases and ~2000 deaths due to vibrio 
cholerae infection are reported (1).  The World Health Organization (WHO) recognizes 
that the actual burden is closer to 1.4-4.3 million cases and 28,000 – 142,000 deaths per 
year (2). It is well accepted that this is a vast underestimation of the total disease burden.  
This reduced reporting is largely affected by the difficulties in diagnosing cholera, which 
includes the difficulties and expense associated with the transportation of samples to a lab 
with the capabilities to confirm cholera infection.  Of the 47 countries which reported 
cholera cases and deaths to the WHO in 2013, 22 of these countries were in Africa.  In 
spite of reporting the largest cholera disease burden in the world, there continues to be a 
poor understanding of the disease patterns in much of Africa and likely further under-
reporting of the disease.   This is due to the challenge of proper disease surveillance and 
laboratory capacity requirements especially in remote/rural areas.  
While population-based surveillance will provide the most accurate information for 
disease burden, it is too resource intensive for most cholera endemic settings.  Sentinel 
surveillance is often employed in resource limited settings to monitor a disease of interest 
at a single or specific sites.  While disease burden estimates are difficult from this type of 
surveillance, this method requires fewer resources while identifying when the disease of 
interest is present (3).  However, even sentinel surveillance is difficult to sustain in low 
resource settings given other health and political priorities and the lack of funding to 
support this concerted effort to track a single disease.  Since 1997, fortnightly 
environmental and clinical surveillance has been conducted in different locations in 




in understanding true disease burden, while providing data to better understand the disease, 
seasonality and transmission patterns(4). 
Diagnostic confirmation of vibrio cholerae infection is challenging in rural and 
resource limited settings.  The gold standard and accepted method of V. cholerae diagnosis 
is through culture confirmation, requiring well-equipped laboratories and trained 
laboratory personnel.  This method is often too time consuming taking 2-3 days for 
confirmation, resource intensive and/or too expensive in these settings.  As a result, cholera 
is often only diagnosed as suspected cases using the clinical definition of having three or 
more loose or liquid stools in the 24-hours with sudden onset in persons > 5 years of age 
prior to presenting (5).  More often, cholera is not diagnosed, and the patient is treated for 
diarrhea without identifying the etiologic agent.  Commercially available dipstick tests, 
such as Crystal VCTM allow for rapid diagnosis.  Previous studies have reported low 
specificity when using the kits with direct testing of stool samples (6-8); however, a 
modified approach to using the dipstick in both stool (9) and environmental specimens (10) 
have recently been demonstrated to successfully improve the sensitivity of the dipstick in 
an urban field setting and a laboratory setting.  In addition, the preservation, storage and 
transportation of positive isolates requires logistical and laboratory support that is often far 
beyond the scope of a rural health facility.  We report the novel use of filter paper 
technology for preservation of specimens for DNA extraction and molecular processing.  
While culture methods are often considered to be the gold standard, they are not 
100% sensitive. For our study, we considered a positive PCR to be a reliable gold-
standard, however, there still could be true positives that are not detected by any of 




 In this study we demonstrate the successful implementation of modified sentinel 
surveillance using low-cost and rapid lab diagnostics in a low-resource setting.  The 
methodology allows for concurrent environmental and clinical surveillance in an effort to 
determine hot spots for cholera activity and cholera transmission patterns while providing 
tools for early detection of cholera.  We hypothesized that there is a reservoir for cholera 
in Lake Chad and that cultureable V cholerae may be detected prior to the onset of an 
outbreak which will allow for rapid response to cases and early intervention in outbreaks 





2.3.1 Study design 
 
 Cameroon has a population of approximately 20 million people, divided into 10 
provinces with extremely varied geographies and several climate zones (25).  The Far 
North region of Cameroon (FNC) is located in the Sahel desert and has a rural population.  
In Cameroon, less than half of the rural population have access to improved drinking water 
(11).  The incidence of cholera disease is becoming increasingly common in Cameroon, 
particularly in the FNC where there were 9 outbreaks between 1996 - 2013; with the 
cholera outbreak in 2010 being the most serious outbreak in decades with almost 10,000 
cases and 599 deaths (a 6.37% CFR) reported just 238 days after the outbreak began (12).  
These numbers are likely an underestimate of the true burden of disease due to lack of 
surveillance and laboratory capacity.   
Diarrhea surveillance was established at 7 seven local health facilities (LHF) in the 




(Mada health District), Ngouma (Makary Health District), and Maltam (Goulfey Health 
District), Blangoua District Medical Center (DMC), Darak DMC, and Naga (Naga Health 
District).  These sites were selected as being geographically representative of the 
Cameroonian health facilities near Lake Chad.  The selected sentinel sites implemented a 
reduced-sampling methodology in which each of the seven sentinel site district health 
facilities enrolled suspected cholera cases of any age into the study for a 3-day period every 
15 days; during this time a trained research assistant is on site at the facility to monitor 
activities.  Additionally, all other days of the month, any patient > 5 years of age presenting 
with diarrhea is identified and asked to participate in the study.  Concurrently, 
environmental sampling began in and around the seven LHF’s.  Three to six environmental 
sites were identified within the health district, and water samples were collected 1 day out 
of every 15 days.  Study enrollment began August, 2013.   
 
2.3.2 Laboratory Methods 
 
Clinical Surveillance 
Fecal specimens or rectal swabs from the consenting diarrhea subjects were 
collected using a stool cup (or from small children, it may also be collected from the diaper).  
These specimens, obtained from the monitoring sites and the sentinel sites, were screened 
for V. cholerae O1 and O139 using an enhanced dipstick method (Crystal VC, Span 
Diagnostics Ltd. 173-B, New Industrial Estate, Road No. 6-G, Udhna, Surat - 394 210, 
INDIA) in which the specimen is tested via dipstick after incubation for 6-8 hours in 
alkaline peptone water (APW).  APW enriched samples which tested positive, as well as a 




for storage until transport for microbiological confirmation in the central reference 
laboratory in the Kousseri Health Facility (Figure 2.1).    
Environmental surveillance 
Surface water samples were collected from 3-6 sites near each of the sentinel health 
facilities (total of 42 sites) to be tested for the presence of V cholerae O1 and O139. Two 
to three liters of the surface water sample was collected in a plastic jar and then filtered 
through sterile gauze.  The gauze is then incubated in APW for 24 hours (+ 2 hours) and 
subsequently tested using the dipstick.  APW positive samples and a 10% sample of 
negative clinical samples were inoculated into Cary-Blair transport media for storage until 
transport for microbiological confirmation in the central reference laboratory in the 
Kousseri Health Facility (Figure 2.2).    
 
Microbiology at the Central Laboratory  
All positive specimens and 10% of negative specimens were sent at routine 
intervals to the central laboratory for confirmation. The specimens were streaked directly 
onto thiosulfate citrate bile salt sucrose (TCBS) agar and incubated for 24 hours at 37°C.  
Immediately after inoculating the first TCBS plate, a pre-labeled APW vial was inoculated 
with the specimen and incubated for 6 hours at room temperature.  After 6 hour incubation, 
a second TCBS plate was inoculated with the enriched specimen and incubated for 24 hours 
at 37°C.   After the 24 hour incubation, any cholera-like colonies were selected with a 
sterile loop, re-suspended in 1-2 drops of PBS and tested via dipstick.  All dipstick positive 
cultures as well as any cultures considered cholera-suspect, demonstrating the morphology 




To evaluate the use of simplified specimen preservation and sample shipping 
methods, clinical and environmental samples from the enriched APW were preserved on 
Whatman 903 filter paper to be tested for vibrios using Polymerase Chain Reaction (PCR) 
methods.  One to two drops of the enriched APW were preserved on Whatman filter paper 
and allowed to air dry; filter paper specimens were stored in individual plastic bags at room 
temperature until they were sent for extraction and PCR processing.   
 
Molecular Biology and Microbiology at the Johns Hopkins Laboratory 
DNA Extraction 
Filter paper specimens were sent at regular intervals for processing in the US.  
Individual DNA extractions were performed by using methods similar to those previously 
published (13). Sterile scissors were used to cut filter paper circles for each dried filter 
paper specimen.  Between samples, the scissors were bleached and rinsed to ensure there 
was no cross contamination when processing the next dried filter paper specimen.  Each 
cut dried filter paper specimen was placed into a pre-labeled tube.  One milliliter (mL) of 
sterile 1X phosphate buffered saline (PBS) was added to each sample tube and incubated 
for 10 minutes at room temperature.  The samples were then centrifuged (14,000 x g for 2 
min) and the supernatant was discarded.  One mL of sterile 1X PBS was then added to each 
sample, and then immediately centrifuged (14,000 x g for 2 min) and the supernatant 
discarded.  Finally, 150ul of a 2% (wt. /vol.) Chelex-100 solution (Bio-Rad, catalog 
no.1422832) was added to each sample.  The samples were placed in a heating block at 




supernatant was removed to a new micro-centrifuge tube and either stored at -20°C or used 
immediately in a PCR amplification reaction. 
PCR 
Multiplex PCR reactions to identify 3 Vibrio species, to differentiate toxigenic and 
non-toxigenic V. cholerae; and to differentiate serogroups 01 and 0139 were conducted in 
a systematic order in conjunction with a 16S bacterial PCR along with Nanodrop 
measurements to confirm extracted DNA quality.  Oligonucleotide primers and their 
respective amplicon sizes are listed in Table 2.1. 
A multiplex PCR amplification was first performed to determine the presence of 
vibrio species in the extracted DNA sample by targeting the toxR genes of V. 
parahemolyticus, V. cholerae, and V. vulnificus. As previously described, the universal 
forward primer UtoxF was used in combination with species specific primers for VvtoxR, 
VptoxR and VctoxR, respectively (14).  The multiplex reaction was run in 50 µL reactions 
containing 5 µL  of extracted DNA, 2x Terra PCR Direct Buffer (with Mg2+, dNTP), 1.25 
U/ µL Terra PCR Direct Polymerase Mix (Clontech Laboratories, Inc., Mountain View, 
California, USA), 30 pmol of the UtoxF primer, and 20pmol of each reverse primer.  PCR 
conditions were optimized at initial denaturation of 4 minutes at 95°C, followed by 30 
cycles  each with denaturation at 95°C for 30 seconds, annealing at 55°C for 30 seconds, 
and extension at 72°C for 30 seconds, with a final extension step of 72°C for 7 minutes 
(Bio-Rad S1000 Thermal Cycler, Hercules, Ca, USA).  The amplified PCR product was 
analyzed by gel electrophoresis on a 1.5% agarose gel and visualized under UV light with 
ethidium bromide.  The products for V. parahemolyticus, V. cholerae, and V. vulnificus 




If V. cholerae was identified in the sample, a multiplex was then used to 
differentiate non-toxigenic and toxigenic V. cholerae.  The multiplex uses primers targeting 
a gene encoding an outer membrane protein (OmpW) that is a unique gene conserved in 
the V. cholerae sequence as well as primers targeting the cholera toxin A (ctxA) gene.  As 
described by Nandi et al (15) the multiplex reaction was run in 25 µL reactions containing 
5 µL of extracted DNA,  2x Terra PCR Direct Buffer (with Mg2+, dNTP), 0.78 U/ µL 
Terra PCR Direct Polymerase Mix (Clontech Laboratories, Inc., Mountain View, 
California, USA), 15pmol of OmpW primers, and 6.2 pmol of ctxA primers.  PCR 
conditions were optimized at initial denaturation of 5 minutes at 94°C, followed by 30 
cycles  each with denaturation at 94°C for 30 seconds, annealing at 64°C for 30 seconds, 
and extension at 72°C for 30 seconds, with a final extension step of 72°C for 7 minutes.  
The amplified PCR product was analyzed by gel electrophoresis on a 1.5% agarose gel and 
visualized under UV light with ethidium bromide.  The products for ompW and ctxA were 
588 and 301 base pairs, respectively. 
All V. cholerae positive specimens were tested to determine if they belonged to 
serogroup 01 or 0139; regardless of their toxigenic nature.  The multiplex uses primers 
targeting unique regions in the rfb gene specific for the 01 and 0139 serogroups.  Following 
methods described by Hoshino et al (16) the multiplex reaction was run in 30 µL reactions 
containing 5 µL of extracted DNA,  2x Terra PCR Direct Buffer (with Mg2+, dNTP), 0.93 
U/ µL Terra PCR Direct Polymerase Mix (Clontech Laboratories, Inc., Mountain View, 
California, USA), and 2µM of 01 and 0139 primers.  PCR conditions were optimized at 
initial denaturation of 5 minutes at 94°C, followed by 30 cycles  each with denaturation at 




with a final extension step of 72°C for 7 minutes.  The amplified PCR product was analyzed 
by gel electrophoresis on a 2% agarose gel and visualized under UV light with ethidium 
bromide.  The products for 01 and 0139 were 192 and 449 base pairs, respectively. 
All samples that test negative for any vibrio species are then tested by 16S rDNA 
PCR to confirm DNA quality.  The primers included a 6968-GC primer which amplifies 
the variable regions 6 and 8 (V6/V8) and primer L1401 to selectively amplify 16S rDNA 
genes.  The methods, as described by Hasan et al consist of a 25ul reaction  containing 5 
µL of extracted DNA,  2x Terra PCR Direct Buffer (with Mg2+, dNTP), 1.25 U/ µL Terra 
PCR Direct Polymerase Mix (Clontech Laboratories, Inc., Mountain View, California, 
USA), 20 µM of 6968-GC and L1401 primers.  PCR conditions were optimized at initial 
denaturation of 2 minutes at 94°C, followed by 35 cycles  each with denaturation at 94°C 
for 30 seconds, annealing at 56°C for 30 seconds, and extension at 68°C for 1 minute, with 
a final extension step of 68°C for 7 minutes.  The amplified PCR product was analyzed by 
gel electrophoresis on a 1.5% agarose gel and visualized under UV light with ethidium 
bromide to reveal the 457 bp amplicon (17). 
 
2.3.3 Statistical Methods 
 
Clinical and Environmental data collected through October 2014 were used for the 
analyses in this report. Descriptive Statistics were used to plot the number of confirmed 
cholera cases and diarrhea comparing intensive versus routine surveillance for each study 
area over the first year of the study.   
The environmental surveillance data included the type of water source (pond, river, 




vibrios in the environment were compared over time by season, facility and water source.  
Loess non-parametric regression methods were used to fit a smooth function of season and 
facility to the presence of cholera (non01 or 01) in the environmental samples.  We 
estimated the significance of Vibrio cholerae 01 detection over the first year of the study, 
taking into account the differing water sources, follow-up visits, and within-facility 
clustering of detection.  We used generalized estimating equations (GEE) with a log link 
function and an ar1 correlation matrix to account for clustering at the facility level. 




2.4.1 Clinical Surveillance 
 
 From August 2013 through October 2014, a total of 949 patients were enrolled in 
the study among all 7 study sites.  575 patients were enrolled in the study during intensive 
surveillance days, 374 patients were enrolled during routine surveillance days (Figure 2.3).  
The figure shows that most cases of acute diarrhea presenting both during the intensive 
surveillance every 15 days and the routine surveillance are not caused by V. cholerae.  
Though cholera was not common, severe diarrheal disease was common in Blangoua 
Health facilities (Figure 2.4). Cholera was not detected in these health facilities until 
October 2014 when a case was detected in Darak, Cameroon.  The outbreak continued in 
Darak through October, with additional cases being detected in nearby Blangoua, 
Cameroon.  In total, 28 clinically confirmed cholera were enrolled during routine 
surveillance days.  Of those presenting with diarrhea on intensive days, most of the patients 




  A cholera outbreak was identified in Darak in early October, followed by 2 clinical 
cases being detected in Blangoua in late October.  Of the 28 patients enrolled in the study 
with confirmed clinical cholera plus two non01 Cholera patients, nearly 40% (11) were 
children under 5 years of age, and nearly 75% were men (Table 2.3).  The sensitivity and 
specificity of the modified protocol for the Crystal VC dipstick is presented in Table 2.2.   
 
2.4.2 Environmental Surveillance 
 
 Between August 27, 2013 and October 31, 2014; 1,012 water samples were 
obtained from the environmental sites for the 7 Health Facilities, of which 244 were V. 
cholerae non-01 positive and 0 where V. cholerae 01 positive.  The four types of water 
sources sampled included rivers, wells, sewage drains and Lake Chad.  Binomial regression 
analysis showed an increased risk of vibrios in April, May and July as compared to the risk 
in January (Figure 2.6).  At the facility level, there was a significantly increased risk of 
vibrio detection at sites near Naga and Darak as compared to Kousseri (Figure 2.7).  Finally, 
as compared to vibrio detection in rivers, there is no significantly increased risk of detection 
at sites along Lake Chad, however a significantly increased risk of vibrio detection was 




 Through this study we found that the simplified laboratory and epidemiological 
surveillance methodologies enabled rapid identification of cases during an outbreak while 
significantly reducing any false positive test results. This study is also the first to 




results of the dipstick test were confirmed by a combination of culture and PCR for 1141 
clinical and environmental samples, demonstrating a specificity of 99.8%.  This is 
significantly higher than the specificity levels reported for direct use of the dipstick in stool 
samples (49-79%) (6-8) and corresponds to similarly improved rates of specificity found 
when used by George et al when used in a hospital setting in Bangladesh (9). 
 This study demonstrates the novel use of filter paper for environmental and stool 
sample preservation for molecular screening.  This method proved to be a low-cost and 
low-maintenance diagnostic for the field setting, eliminating the need for culture 
confirmation and the intensive laboratory reagents and level of trained laboratory personnel 
needed to conduct the microbiological testing.  The filter paper preservation is a simple 
blotting method that can be performed by non-lab personnel in a field setting.  The filter 
paper does not need a cold chain for preservation and is not considered a biohazardous 
material, easing transport issues.  The conventional culture techniques were conducted on 
all positive samples and 10% of negatives in this study; and the results were identical to 
PCR findings. 
This study is the first to investigate a simplified epidemiological and laboratory 
surveillance methodology for use in remote and rural settings, and to successfully 
implement a sustained clinical and environmental surveillance of cholera in the Far North 
of Cameroon, particularly during a period of insecurity.   While it was modeled after a 
similar methodology used in Bangladesh (4), the method in Cameroon was further 
simplified with the use of a modified rapid dipstick test, the use of a low cost gauze 
filtration device for environmental sampling, and the demonstration of dried, enriched 




not only was epidemiological surveillance possible with 3 days of intensive surveillance 
every 15 days, but that incorporation of this surveillance into routine practices was possible.  
After more than one year of surveillance, the first cholera cases in Blangoua health district 
in 2014 were identified during our surveillance activities and the cases were confirmed 
using our laboratory methodologies in a rapid manner.  This is important not only for the 
identification of a surveillance methodology that is feasible in remote and vulnerable 
settings, but also to demonstrate that this method can result in early outbreak detection, 
enabling rapid response and intervention to prevent further spread of the disease. 
 The surveillance results for the first year of this study did not confirm our initial 
hypothesis that there is a reservoir for cholera in Lake Chad.  Nor did the regression 
analysis reveal a significant seasonal trend in vibrio presence in the environmental sites.  
However, this report is based only on the first year of surveillance.  Given that outbreaks 
in the study area were only in the beginning stages at the conclusion of this first report, the 
surveillance data for year 2 of the study will provide an interesting comparison to year 1.  
 There are several limitations to this study, the most important being that the study 
site is in a vulnerable area that continues to struggle with safety and security issues as a 
result of a terrorist group.  Safety issues led to loss of data in some study areas, particularly 
Darak which is located in Lake Chad.  The presence of non-toxigenic V. cholerae 01 in the 
environmental sources during the early months of 2014 in Darak may have been an early 
warning sign for the area; however, the team was unable to maintain regular surveillance 
in this area to enable a complete analysis of events leading to the toxigenic V. cholerae 
outbreak in the fall of 2014.  Clinical cholera cases were confirmed in Darak health district 




this study report is for the period of study initiation in August 2013 through October 2014.  
There were no clinical cases identified in our study area prior to October 2014; therefore 
we have limited positive results to power a case-control study.  This limited positive sample 
size also likely negatively affected the reported dipstick sensitivity.  Finally, in this study 
we clinically confirmed only V. cholerae, and therefore, were unable to further characterize 
the cases of non-cholera diarrhea enrolled in the study. 
 In conclusion, the first year of this surveillance study demonstrates the successful 
use and implementation of low-cost, simplified epidemiological and laboratory 
methodologies for surveillance in remote, rural or vulnerable settings.  This study 
demonstrates the use of a modified dipstick protocol can be implemented in a field setting 
with improved specificity.   The application of basic technologies such as the use of gauze 
filtration rather than more expensive filtration methods decreases supply and logistics costs, 
and allows for important environmental surveillance to provide information about the 
burden of cholera in previously undescribed areas.  The application of dried filter paper 
methodology to cholera DNA preservation is novel and demonstrates a simplified method 




































































Table 2.1: Oligonucleotide Primers for PCR assays 
Primer Name Sequence Amplicon Reference 
UtoxF GASTTTGTTTGGCGYGARCAAGGTT  (14) 
vptoxR GGTTCAACGATTGCGTCAGAAG 297bp (14) 
vctoxR GGTTAGCAACGATGCGTAAG 640bp (14) 
vvtoxR AACGGAACTTAGACTCCGAC 435bp (14) 
CtxA-F CTCAGACGGGATTTGTTAGGCACG 302 bp (15) 
CtxA-R TCTATCTCTGTAGCCCCTATTACG  (15) 
ompW-F CACCAAGAAGGTGACTTTATTGTG 588 bp (15) 
ompW-R GAACTTATAACCACCCGCG  (15) 
O1F2-1 GTTTCACTGAACAGATGGG 192bp (16) 
O1R2-2 GGTCATCTGTAAGTACAAC  (16) 
O139F2 AGCCTCTTTATTACGGGTGG 449bp (16) 
O139R2 GTCAAACCCGATCGTAAAGG  (16) 
6968 GC (V6/V8) 5’ – AA CGC GAA CCT TAC – 3’ 457bp (17) 



































































































































Table 2.2: Positive and Negative Predictive Values, Sensitivity and Specificity of Crystal 





































































































Figure 2.5 Multiplex PCR differentiating toxigenic V. cholerae strains of environmental 


































Figure 2.5: PCR of environmental samples from the Darak region; testing for the ompW gene (specific for Vibrio cholerae) and 
for the ctxA gene (testing for cholera toxin gene).  Only the control strains were positive for ctxA, demonstrating that the 
specimens from Darak are non-toxigenic V. cholerae strains.   
<- 588bp ompW Gene 
<- 301bp ctxA Gene 






































Figure 2.7: Cholera presence in environmental specimens (non-toxigenic non01 Cholera 
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There has been limited research characterizing the molecular epidemiology of Vibrio 
Cholerae in Africa.  Knowledge of the genetic diversity of toxigenic V. cholerae strains 
provides understanding of strain relationship, epidemic potential, and transmission patterns.  
The constraints in facilitating this understanding is not only the lack of regular cholera 
disease surveillance in Africa, but also the lack of laboratory capabilities to preserve, store 
and ship isolates in a timely manner.  We evaluate the use of simplified sample preservation 
methods for molecular characterization using MLVA for differentiation of Vibrio cholerae 
genotypes. 
Methods 
A sentinel surveillance study was conducted to assess simplified laboratory and 
epidemiological surveillance methodologies to assess cholera disease burden in a remote 
setting in the Far North of Cameroon. A total of 1,000 clinical cases were enrolled at the 
district health facilities and 1,012 environmental samples were processed among 45 distinct 
water sites.   We assessed the genetic relatedness among 66 V. cholerae isolates and crude 
clinical and environmental specimens from Cameroon at 5 loci containing variable tandem 
repeats.  The samples were collected from two geographically distinct outbreaks in the 
FNC in June 2014 and October 2014.  In addition, we compared the genetic relatedness of 
the Cameroon samples to isolates from outbreaks in the Philippines and Mozambique.  
Results 
Isolates from 57 individual patients were analyzed; of these samples 16 were analyzed in 




crude specimens preserved on filter paper allowed for successful genetic characterization 
as compared to the culture isolates.  The specimens from Cameroon formed two distinct 
clonal clusters distinct to each outbreak in 2014, however, specimens from the two 
outbreaks were identical at 3 loci indicating a relationship between the strains.  One isolate 
from Mozambique was related to the June 2014 Cameroon outbreak samples.  Samples 
from the Philippines were distinct from African samples, and formed two distinct clonal 
clusters. 
Conclusions 
  The study demonstrated that the use of simplified laboratory diagnostics in remote 
and low-resource settings allows for the rapid identification of V. cholerae 01, and further, 
simplified DNA preservation methods facilitate timely molecular characterization of 
outbreak samples.  The implementation of these methodologies can allow timely 
understanding of disease transmission patterns and enable proper planning and intervention 
targeting to prevent further disease spread.  The molecular characterization did not suggest 
significant genetic diversity among strains in the Far North of Cameroon, rather that the 
outbreaks in 2014 were related despite being geographically distinct.  The genetic 
relatedness shown between strains from Cameroon and Mozambique highlights the need 
for continued molecular epidemiological research to better understand the transmission and 










The Vibrio genus includes several different species which are known to be pathogenic, 
including Vibrio parahemolyticus, Vibrio vulnificus, and Vibrio alginolyticus.  But the 
most widely known of these species is Vibrio cholerae.  The etiologic agent of cholera, 
Vibrio cholerae, has more than 200 serogroups, differentiated by the O-antigen on the 
lipopolysaccharide (LPS) of the bacteria’s outer membrane (1).  Of these 200 serogroups, 
only two that produce cholera toxin (CT) are known to cause epidemic disease, serogroups 
01 and 0139 (2).  Vibrio species, and even differentiating pathogenic from nonpathogenic 
V. cholerae can generally be differentiated using basic biochemical and serological 
techniques (1).  However, more advanced molecular techniques are needed to differentiate 
between different pathogenic strains; which provides crucial information to understand 
whether distinct isolates cause outbreaks in different geographic areas or whether there are 
common isolates that spread through wide geographic areas. 
As previously described by Kendall et al, there are a number of molecular methods that 
have been established for differentiating between V. cholerae strains.  These include rRNA 
restriction fragment length polymorphism (ribotyping), pulsed-field gel electrophoresis 
(PFGE), and multilocus sequence typing (MLST).  Due to the genetic similarity among 
clinical isolates, these methods have limited ability to differentiate the “near clonality” 
between pathogenic strains (3).  Multi-locus variable-number tandem-repeat (VNTR) 
analysis (MLVA) examines short repeat DNA sequences that are repeated at a specific 
locus.  The method uses the number of repeats at each specific locus to differentiate 




To date, many of the studies published using MLVA methods to characterize V. 
cholerae strains have focused on the endemic areas of south Asia (4, 5). A study examining 
environmental strains in comparison to clinical strains was performed in Bangladesh.  The 
results from this research demonstrated that the vibrios were endemic in the aquatic 
environment in the study area of Bankerganj (6).  Subsequent MLVA analysis on both 
clinical and environmental specimens demonstrated that the specimens collected from 
either small outbreak site, Bankerganj or Mathbaria, were distinct V. cholerae populations 
relative to the outbreak site.  Additionally, they found that clinical or environmental isolates 
from a given time period were more likely to have a common sequence type (ST) than 
those collected in a subsequent month or time period.  The sample size was small and 
produced only a few clinical and environmental isolates (i.e. 2 of 24 in Bankerganj, 1 of 
16 in Mathbaria) in which the sequence types were the same.  Thus, further research is 
warranted to assess the suggested benefits of using VNTR ST’s to determine genetic 
relatedness during outbreaks, especially in geographic areas such as sub-Saharan Africa 
where the epidemiology  likely differs from that of Bangladesh (7).   
There has been limited research on the molecular characterization of cholera in Africa, 
and even less research in regards to understanding the molecular epidemiology of cholera 
in Africa.   As the genetic diversity of toxigenic V. cholerae strains increases; it is 
increasingly important to understand their relationships and their epidemic potential (8).  
One of the most recent studies published in 2012 characterized strains isolated in Kenya.  
The study reported MLVA characterization of clinical isolates from outbreaks beginning 
in January of 2009.  The demonstration of multiple distinct lineages that were also 




were the result of endemic V. cholerae rather than imported cases or those spread by 
travelers (9).   The continued use of MLVA for differentiation of clinical cholera isolates 
as well as any potential environmental isolates may provide further evidence of endemic 
foci.   
Reports identifying the El Tor variant strain expressing the classical enterotoxin as the 
predominant strain in the world, including in Africa, were most recently confirmed by a 
ten year study in Zambia.  The study emphasized the importance of further study and 
characterization of these altered strains to monitor their evolution as there has been a 
continuous change in the pattern of strains in potentially epidemic areas over the past 
decade (8).  The proposed methods contribute new and timely information about the 
genetic diversity of cholera in Africa and elsewhere worldwide, using simple and efficient 
laboratory methods.  These methods can provide crucial information to understand whether 
these outbreaks arise from the same strain, suggesting cholera spread; or whether the 
outbreaks represent unique strains and individually arising outbreaks. 
In this study, we compare clinical samples obtained from two recent but geographically 
distinct outbreaks in Cameroon in which the samples were collected using simplified field 
surveillance methods.  Field collected samples as well as culture isolates were preserved 
on Whatman filter paper, then sent for MLVA characterization.  In addition, we compared 
the Cameroon strains to those collected using conventional methods from Mozambique in 
recent years as well as isolates from a recent 2014 outbreak in the Philippines.  The results 
demonstrate that using the simplified methods, MLVA analysis and pathogenic vibrio 
strain differentiation is possible using crude DNA extracts from filter paper preserved 




time and geography, are related.  Interestingly, we found that an isolate from Mozambique 
belongs to the same clonal cluster as specimens from the Cameroon outbreak in Bourrha 
in June 2014.  The specimens from the Philippines were distinct from the African 
specimens; the 2014 Philippines were completely distinct from the 2012 and 2013 isolates, 
forming 2 different clonal complexes. 
3.3 Methods 
 
3.3.1 V. cholerae strains 
 
 A total of 92 V. Cholerae isolates and crude specimens were included in this study.  21 
V. cholerae isolates from Bourrha Health District, Hina Health District and Mogode Health 
district in the Far North of Cameroon were collected during a cholera outbreak in June 
2014, 18 V. cholerae crude specimens preserved on filter paper plus their corresponding 
culture isolates from Darak, Cameroon collected during a cholera outbreak in October 2014 
plus 3 additional isolates from the Darak outbreak, 2 V. cholerae crude specimens 
preserved on filter paper plus their corresponding culture isolates from clinical surveillance 
conducted in Blangoua, Cameroon in October 2014, and 2 environmental crude specimens 
isolated during environmental surveillance in Naga, Cameroon in mid-September and mid-
October 2014.  In addition, 15 isolates from the Philippines (4 from an outbreak in 
December, 2012 in Lopez, Quezon; 6 from outbreaks in 2013:3 from Sinawal, General 
Santos City in April 2013 and 3 from T’boli, S. Cotabato in May 2013; and 5 from the 
2014 outbreak in Davao del Sur) and 4 isolates from Manhica, Mozambique January 2008 
outbreak and 1 isolate from Manhica, Mozambique February 2009. 





Clinical and environmental surveillance was initiated in the Far North of Cameroon (FNC) 
in August 2013.  Surveillance was established at 7 seven local health facilities (LHF) in 
the FNC, in and around Lake Chad, including: Kousseri, Mada, Ngouma, Maltam, 
Blangoua, Darak, and Naga (Figure 3.1).  In June of 2014, the surveillance team was 
notified of an outbreak in the Bourrha Health District outside of the study surveillance area; 
the team was deployed to assist applying the study’s simplified field diagnostics to provide 
rapid diagnosis and confirmation of cases.  During the time the surveillance team was 
aiding the health district, 21 cases were confirmed and 21 isolates were preserved for 
molecular characterization.  In October 2014, a clinical outbreak was detected in the Darak 
study area; from October 19 – October 25, 2014, 21 clinical cases were confirmed using 
simplified lab diagnostics.  The original field specimen and a culture isolate of each sample 
were preserved on filter paper for further molecular characterization.  Shortly after the 
onset of the outbreak in Darak, two clinical cases were identified during study surveillance 
activities at the Blangoua Health Facility.  Similarly, these two clinical cases were 
confirmed using simplified laboratory diagnostics and the field specimen plus a culture 
isolate were preserved on filter paper for comparison to the previous outbreak samples.  2 
environmental samples collected during this time period at the Naga field sites also tested 
positive for V. cholerae and were preserved for molecular testing.  
3.3.3 Laboratory Methods 
 
Clinical Surveillance 
Fecal specimens or rectal swabs from the consenting diarrhea subjects were 
collected using a stool cup (or from small children, it may also be collected from the diaper.  




for V. cholerae O1 and O139 using an enhanced dipstick method (Crystal VC, Span 
Diagnostics Ltd. 173-B, New Industrial Estate, Road No. 6-G, Udhna, Surat - 394 210, 
INDIA) in which the specimen is tested via dipstick after incubation for 6-8 hours in 
alkaline peptone water (APW).  APW enriched samples which tested positive, as well as a 
10% sample of negative clinical samples were inoculated into Cary-Blair transport media 
for storage until transport for microbiological confirmation in the central reference 
laboratory in the Kousseri Health Facility.  To evaluate the use of simplified specimen 
preservation and sample shipping methods, the enriched APW specimen for each sample 
was also preserved on Whatman 903 filter paper to be tested for vibrio’s using molecular 
methods.  1-2 drops of the enriched APW was aliquoted to the Whatman filter paper and 
allowed to air dry; filter paper specimens were stored in individual plastic bags at room 
temperature until they were sent for extraction and PCR processing.   
Environmental surveillance 
Surface water samples were collected from 3-6 sites near each of the sentinel health 
facilities (total of 45 sites) to be tested for the presence of V cholerae O1 and O139. 2-3 
Liters of the surface water sample was collected in a plastic jar and then filtered through 
sterile gauze.  The gauze is then incubated in APW for 24 hours (+ 2hours) and 
subsequently tested using the dipstick.  APW positive samples and a 10% sample of 
negative clinical samples were inoculated into Cary-Blair transport media for storage until 
transport for microbiological confirmation in the central reference laboratory in the 
Kousseri Health Facility.   Similarly to clinical samples, the enriched APW specimen for 
all samples were preserved on Whatman filter paper for preservation for future molecular 




allowed to air dry; filter paper specimens were stored in individual plastic bags at room 
temperature until they were sent for extraction and PCR processing.   
Microbiology at the Central Laboratory  
Positive clinical and environmental specimens were streaked directly onto 
thiosulfate citrate bile salt sucrose (TCBS) agar and incubated for 24 hours at 37°C.  
Immediately after inoculating the first TCBS plate, a pre-labeled APW vial will be 
inoculated with the specimen and incubated for 6 hours at room temperature.  After 6 hour 
incubation, a second TCBS plate is inoculated with the enriched specimen and incubated 
for 24hours at 37°C.   After the 24hour incubation, any cholera-like colonies were selected 
with a sterile loop, re-suspended in 1-2 drops of PBS and tested via dipstick.  All dipstick 
positive cultures as well as any cultures considered cholera-suspect, demonstrating the 
morphology of a cholera colony, were preserved in nutrient agar for further testing. 
   Microbiology at the Central Laboratory  
All positive specimens were sent to the central laboratory in Kousseri, Cameroon 
for confirmation. The specimens were streaked directly onto thiosulfate citrate bile salt 
sucrose (TCBS) agar and incubated for 24 hours at 37°C.  Immediately after inoculating 
the first TCBS plate, a pre-labeled APW vial will be inoculated with the specimen and 
incubated for 6 hours at room temperature.  After 6 hour incubation, a second TCBS plate 
is inoculated with the enriched specimen and incubated for 24hours at 37°C.   After the 
24hour incubation, any cholera-like colonies were selected with a sterile loop, re-
suspended in 1-2 drops of PBS and tested via dipstick.  All dipstick positive cultures as 




cholera colony, were preserved in nutrient agar as well as blotted (using PBS to dissolve 
colony) onto Whatman Filter paper for further testing. 
Molecular Characterization 
DNA Extraction 
DNA extractions of filter paper specimens were performed by using methods 
similar to those previously published (10). Sterile scissors were used to cut filter paper 
circles for each dried filter paper specimen.  Between samples, the scissors were bleached 
and rinsed to ensure there was no cross contamination when processing the next dried filter 
paper specimen.  Each cut dried filter paper specimen was placed into a pre-labeled tube.  
1 milliliter (mL) of sterile 1X phosphate buffered saline (PBS) was added to each sample 
tube and incubated for 10 minutes at room temperature.  The samples were then centrifuged 
(14,000 x g for 2 min) and the supernatant was discarded.  1 mL of sterile 1X PBS was 
then added to each sample, and then immediately centrifuged (14,000 x g for 2 min) and 
the supernatant discarded.  Finally, 150ul of a 2% (wt. /vol.) Chelex-100 solution (Bio-Rad, 
catalog no.1422832) was added to each sample.  The samples were placed in a heating 
block at 100°C for 8 minutes.  The samples were centrifuged (14,000 x g for 2min) and the 
supernatant was removed to a new microcentrifuge tube and either stored at -20°C or used 
immediately in a PCR amplification reaction. 
Toxigenic V. cholerae 01 was confirmed for all samples sent for sequencing using 
a multiplex targeting a gene encoding an outer membrane protein (OmpW) that is a unique 
gene conserved in the V. cholerae sequence as well as primers targeting the cholera toxin 
A (ctxA) gene.  As described by Nandi et al (11) the multiplex reaction was run in 25 µL 




dNTP), 0.78 U/ µL Terra PCR Direct Polymerase Mix (Clontech Laboratories, Inc., 
Mountain View, California, USA) 15pmol of OmpW primers, and 6.2 pmol of ctxA 
primers.  PCR conditions were optimized at initial denaturation of 5 minutes at 94°C, 
followed by 30 cycles  each with denaturation at 94°C for 30 seconds, annealing at 64°C 
for 30 seconds, and extension at 72°C for 30 seconds, with a final extension step of 72°C 
for 7 minutes.  The amplified PCR product was analyzed by gel electrophoresis on a 1.5% 
agarose gel and visualized under UV light with ethidium bromide.  The products for ompW 
and ctxA were 588 and 301 base pairs, respectively (Figure 3.2). 
Subsequently, all specimens were tested to determine if they belonged to serogroup 
01 or 0139 with a multiplex targeting unique regions in the rfb gene specific for the 01 and 
0139 serogroups.  Following methods described by Hoshino et al (12) the multiplex 
reaction was run in 30 µL reactions containing 5 µL of extracted DNA,  2x Terra PCR 
Direct Buffer (with Mg2+, dNTP), 0.93 U/ µL Terra PCR Direct Polymerase Mix 
(Clontech Laboratories, Inc., Mountain View, California, USA) 2µM of 01 and 0139 
primers.  PCR conditions were optimized at initial denaturation of 5 minutes at 94°C, 
followed by 30 cycles  each with denaturation at 94°C for 1 minutes, annealing at 55°C for 
1 minute, and extension at 72°C for 1 minute, with a final extension step of 72°C for 7 
minutes.  The amplified PCR product was analyzed by gel electrophoresis on a 2% agarose 
gel and visualized under UV light with ethidium bromide.  The products for 01 and 0139 
were 192 and 449 base pairs, respectively (Figure 3.3). 
MLVA analysis 
The V. cholerae 01 positive samples were then genotyped at the five previously 




Each locus was amplified using VNTR-specific primers (Table 3.1) and PCR conditions 
described previously (3, 5). Briefly, VC0147 and VCA0171 PCR products were amplified 
in 1 combined reaction while VC0283, VC0437, and VC1650 PCR products were a second 
separate reaction.  Both reactions were comprised of a total reaction of 30 µL containing 3 
µL of 10X PCR Buffer, 1.2 mM dNTPs, 50 mM MgCl2, 0.2 µL of 5 U Taq Polymerase,  
and 1 µM of each forward and reverse primers.  PCR conditions for VC0147 and VCA0171 
primers  were optimized at initial denaturation of 5 minutes at 95°C, followed by 35 cycles  
each with denaturation at 95°C for 1 minute, annealing at 58°C for 45 seconds, and 
extension at 72°C for 1 minute, with a final extension step of 72°C for 4 minutes.   PCR 
conditions for VC0283, VC0437, and VC1650  primers were optimized at initial 
denaturation of 5 minutes at 95°C, followed by 35 cycles  each with denaturation at 95°C 
for 1 minute, annealing at 55°C for 45 seconds, and extension at 72°C for 1 minute, with a 
final extension step of 72°C for 4 minutes.   The presence of amplified products was 
confirmed by gel electrophoresis; the amplified products were then purified using Millipore 
Manu filter plates (Merck, Darmstadt, Germany).  The purified products were sequenced 
using a 3730xl Automatic Sequencer and the size was determined using internal lane 
standards with the GeneScan program (all from Applied Biosystems, ABI, Life 
Technologies Grand Island, NY) in combination with the formulae in Table 3.1.  Alleles 
were determined by the number of repeats at each locus, and the number of repeats were 
listed in order of the five VNTR Loci to generate an isolate genotype: VC0147, VC0437, 
VC1650, VCA0171, and VCA0283 (Table 3.2).  Therefore the genotype 6 4 6 17 20 
indicates 6 repeats at the locus VC0147, 4 at the promoter of VC0437, etc. (3).  Genetic 






 DNA was successfully analyzed from 82 of 89 initial specimens.  Of these 82 
specimens, 17 were analyzed in two forms: culture isolate and APW enriched stool sample 
(crude specimen).  The isolates sequence types were identical to the crude sample sequence 
types in 15 of 16 patients.  One isolate was 01 dipstick negative in contrast to the crude 
specimen which was 01 dipstick positive. PCR verified this isolate was a non-toxigenic V. 
cholerae non 01 isolate.  This specimen was sent in error, as the colony morphology may 
not differ from that of a toxigenic V. cholerae 01, signifying that this was a mixed culture 
and therefore would not match the 01 crude specimen.  Since the correct V. cholerae 01 
isolate was not sent as a 01 positive to be compared for sequencing it is not included in the 
final comparison.  One isolate differed from its crude specimen genotype at the 4th locus, 
suggesting that the person was infected with multiple strains.  In addition, 2 environmental 
samples filtered and then enriched in APW (crude specimen) were also analyzed.  DNA 
for MLVA genotype analysis except for the 5 isolates from Manhica, Mozambique were 
preserved and shipped for sequencing using Whatman filter paper and extracted according 
to the novel methods presented here.   When all five loci were considered, there were 28 
distinct genotypes among the 82 specimens analyzed (Table 3.2).  The number of distinct 
alleles among the isolates at loci VC0147, VC0437, VC1650, VCA0171, and VCA0283 
were 8, 2, 7, 13 and 9, respectively.  Genotypes were defined as a clonal complex, when 
the genotypes were related to each other by an allelic change at a single locus. Five clonal 





 The Cameroon isolates belonged to two main clonal complexes, 1 and 3 (Figure 
3.4).  Clonal complex 1 contained 7 different genotypes from 20 isolates from the same 
outbreak in the Bourrha district in June 2014. The center of the clonal complex is known 
as the “founder” and is defined as the genotype with the largest number of single-locus 
variants (SLVs) (13).  In clonal complex 1, the founder genotype (9-4-6-17-20) was present 
in 11 Bourrha clinical isolates.  The 5 genotypes diverging from the founder were clinical 
isolates from the Bourrha outbreak (9-4-6-17-20; 9-4-6-18-20; 9-4-6-17-19; 9-4-6-17-21; 
and 9-4-6-17-23).  Of these 5 genotypes, the last differentiated further with genotype 9-4-
6-18-23 from a Mozambique clinical sample from an outbreak in February of 2009. 
 Clonal complex 3 contains 4 genotypes from 26 isolates and 18 enriched stool 
samples.  The founder genotyped (9-4-6-16-25) was observed in 28 isolates and enriched 
stool specimens predominantly from the outbreak on the island of Darak in October 2014; 
with one clinical sample (both isolate and enriched stool specimen) from the Blangoua 
Health District in October 2014.  3 genotypes radiated from the founder, the first two 
genotypes 9-4-6-14-25 and 9-4-6-12-25 were from isolates and stool samples from the 
Darak Outbreak and the third 9-4-6-15-25 was from an isolate and stool sample from the 
Blangoua Health District.  While this clonal complex is technically distinct from clonal 
complex 1 as by definition they differ at more than 1 loci; Clonal complex 1 and 3 are 
identical at the first 3 loci (9-4-6-X-X), demonstrating a clonal relationship between the 
two complexes. 
 The Philippine isolates comprised clonal complexes 2 and 4.  The isolates from the 
outbreaks in Lopez, Quezon in 2012 and T’boli South Cotabato in 2013 clustered in clonal 




9-10-17-22).  While the isolates from the outbreak in July 2014 in Davao del Sur comprised 
clonal complex four which has 3 genotypes (12-9-8-22-27; 12-9-9-22-27; 12-9-9-23-27). 
 Of the five specimens from Mozambique included in this analysis; 3 isolates 
clustered together into 2 genotypes in clonal complex 5, 1 isolate was a singleton, and 1, 
as previously mentioned, was a genotype in clonal complex 1. 
 There were 6 additional singletons, including 3 singletons from Philippine isolates; 
1 from the outbreak in Lopez, Quezon in 2012, and 2 singletons from 2013 in Sinawal, 
General Santos City in April and May 2013, respectively.  2 environmental specimens 
isolated from Naga Health District in September and October yielded 2 distinct singletons; 
both of which were identified by dipstick and PCR to be a non01 toxigenic Vibrio cholerae.  
Variation between the culture isolate from a single stool sample and the crude stool 
specimen yielded 2 genotypes (9-4-6-12-25 and 9-4-6-16-25), the variants are related 




 The results of this study show foremost that using the simplified laboratory 
diagnostics in vulnerable and remote field settings enables the rapid identification in the 
field of Vibrio cholerae 01 (and 0139) positive clinical and environmental samples.  Further, 
the use of the simplified DNA preservation method allows for sample storage and transport 
in difficult settings.  As a result of the implementation of these techniques, we were able 
to characterize an on-going outbreak molecularly.  These rapid results can provide key 
stakeholders in the country information regarding disease transmission patterns to allow 




 The comparison of 16 culture confirmed Vibrio cholerae 01 isolates to the mixed 
stool cultures preserved on filter paper successfully demonstrated that there is no difference 
in the genotypic results regardless of the method in which the sample is preserved for 
molecular characterization.  In settings in which classical microbiological methodologies 
for culturing and identifying positive V. cholerae clones is not possible due, these 
simplified methods have shown to produce identical results as a low cost, low maintenance 
alternative to characterize Vibrio strains.  
The results of the genetic analyses did not suggest significant genetic diversity 
within Cameroon; rather that the 2014 outbreaks in Cameroon beginning in Bourrha Health 
District in May 2014 and continuing through June 2014 are related to the currently on-
going outbreaks in the Darak and Blangoua Health Districts.  Given that the two outbreaks 
comprised distinct clonal complexes, the results suggest that the outbreak strain that has 
mutated.  Due to the difference in 2 loci and the limited samples, it is not clear whether the 
related strains were spread by travelers in the region or whether this strain persists in the 
Far North region on a small scale, and conditions were favorable in 2014 for its spread.  
Interestingly, one isolate from Manhica, Mozambique in 2009 was identified as being 
related to the strains present in the Bourrha outbreak in Cameroon.  Given that the 
Mozambique strain is older than the strain present in the 2014 outbreaks in Cameroon, it 
suggests further investigation is warranted into strains from previous Cameroon outbreaks.  
This may suggest that the strain was carried from Mozambique to Cameroon, where it 
found suitable conditions to persist until outbreak conditions provided an environment 




The outbreaks in 2014 in Philippines are clearly distinct from those in Cameroon 
and Mozambique.  However, the identification of two clonal complexes demonstrates that 
the 2014 outbreak in Davao del Sur is distinct from the 2012 and 2013 outbreaks.  The use 
of filter paper preservation of isolates was used to enable shipment of DNA only for timely 
molecular characterization of the 2014 strains in comparison to those from previous years. 
There are limitations to this study, including the difficulty in obtaining data and 
samples consistently due to concerns about security and safety of the staff in the outbreak 
areas in the Far North of Cameroon in 2014.  While our study team was able to assist with 
outbreak in Bourrha, Cameroon, the presence of an insurgent group prevented further 
epidemiological characterization of the outbreak.  The team was able to train the local 
health staff in our simplified diagnostics techniques for confirming cholera, however, our 
ability to collect specimens and their associated epidemiological information was limited 
as it was not safe for the team to work in the area for long periods.  The same situation 
applies to the island of Darak in Lake Chad where an outbreak is still on-going.  While this 
is a regular study site, surveillance has been difficult in 2014 with long interruptions due 
to safety issues.  As a result of these conditions, environmental sampling was not possible 
during the outbreak to investigate a potential relationship between the clinical and 
environmental strains.  However, our study is conducting environmental and clinical 
surveillance in surrounding Health Districts to monitor for potential disease spread.  In 
addition, the comparison to Mozambique strains to those from Cameroon, while 
demonstrating a relationship in clonal complex 1, is limited, as this study area is not 




were limited.  Further research is warranted to better understand the relationship among 
these strains. 
In conclusion, this study demonstrates that simple and low-cost lab methods can be 
utilized in even the most vulnerable and resource limited settings and allow for molecular 
characterization of cholera outbreaks in a rapid and timely manner.  The molecular data 
gathered in this study was promptly presented to the Ministry of Health of Cameroon to 
proactively plan interventions in the outbreak and surrounding areas in the Far North, to 
include a potential vaccination campaign and behavioral interventions.  The ability to 
provide timely information to aide in outbreak response and intervention measures is 
critical to reduce disease burden and death.   
In addition, we show clearly that the strains present in 2014 outbreaks in South-east 
Asia are distinct from those in Africa.  Interestingly, we did show a relationship between 
strains present in the 2014 outbreaks in Cameroon and those isolated from Mozambique, 
two geographically distant nations in Africa.  This finding and in addition to the fact that 
the strains in the two outbreaks in distinct areas of the Far North of Cameroon are similarly 
related warrants continued surveillance molecular characterization in these areas to 




































































































Table 3.1: VNTR Primers and Formulae for V. cholerae MLVA 
Primer 
Name Sequence Range Formula 




 VC0147-R TET-ACGTGCAGGTTCAACCGTG 




 VC0437-R TET-GTTGCCGCCATCACCAGCTTG 




 VC1650-R TET-CCGCTAACTGAGTGACCGC 




 VCA0171-R FAM-AGGCGCCTGATGACGAATCC 




































Table 3.2: V. cholerae Isolate Genotypes and MLVA group 
 
Original ID Location, Year VC0147 VC0437 VC1650 VCA0171 VCA0283 MLVA Group 





















Strains 8 4 6 19 21 5 
5B_Cam Bourrha, CMR; June 2014 9 4 6 17 19 
1 
12B_Cam Bourrha, CMR; June 2014 9 4 6 17 19 
1 
6B_Cam Bourrha, CMR; June 2014 9 4 6 17 19 
1 
25B_Cam Bourrha, CMR; June 2014 9 4 6 18 20 
1 
14B_Cam Bourrha, CMR; June 2014 9 4 6 17 20 
1 
21B_Cam Bourrha, CMR; June 2014 9 4 6 17 20 
1 
7B_Cam Bourrha, CMR; June 2014 9 4 6 17 20 
1 
20B_Cam Bourrha, CMR; June 2014 9 4 6 17 20 
1 
23B_Cam Bourrha, CMR; June 2014 9 4 6 17 20 
1 
22B_Cam Bourrha, CMR; June 2014 9 4 6 17 20 
1 
11B_Cam Bourrha, CMR; June 2014 9 4 6 17 20 
1 
24B_Cam Bourrha, CMR; June 2014 9 4 6 17 20 
1 
26B_Cam Bourrha, CMR; June 2014 9 4 6 17 20 
1 
29B_Cam Bourrha, CMR; June 2014 9 4 6 17 20 
1 
28B_Cam Bourrha, CMR; June 2014 9 4 6 17 20 
1 





Strains 9 4 6 18 23 
1 






11 4 1 13 14 Singleton 
013B PHIL. Lopez, Quezon, PHL; Dec2012 11 9 10 17 20 2 









11 9 10 14 24 Singleton 
011B PHIL. 
Davao del Sur, 
PHL; 
July 2014 
12 9 8 22 27 4 
005B PHIL. 
Davao del Sur, 
PHL; 
July 2014 
12 9 9 22 27 4 
012B PHIL. 
Davao del Sur, 
PHL; 
July 2014 
12 9 9 23 27 4 
010B PHIL. 
Davao del Sur, 
PHL; 
July 2014 










12 9 10 17 22 2 
600070-DN Darak,CMR; Oct 2014 8 4 7 10 25 Singleton 
221442 Naga,CMR; Oct 2014 15 4 6 12 24 Singleton 
600068-DP Darak,CMR; Oct 2014 9 4 6 12 25 3 
600059-DP Darak,CMR; Oct 2014 9 4 6 14 25 3 
600052-DP Darak,CMR; Oct 2014 9 4 6 14 25 3 
600052-DR Darak,CMR; Oct 2014 9 4 6 14 25 3 
600066-DR Darak,CMR; Oct 2014 9 4 6 14 25 3 
600064-DR Darak,CMR; Oct 2014 9 4 6 14 25 3 
600072-DP Darak,CMR; Oct 2014 9 4 6 14 25 3 
600058-DP Darak,CMR; Oct 2014 9 4 6 14 25 3 
600066-DP Darak,CMR; Oct 2014 9 4 6 14 25 3 
600071-DP Darak,CMR; Oct 2014 9 4 6 14 25 3 
600064-DP Darak,CMR; Oct 2014 9 4 6 14 25 3 
600059-DR Darak,CMR; Oct 2014 9 4 6 14 25 3 
600058-DR Darak,CMR; Oct 2014 9 4 6 14 25 3 
600071-DR Darak,CMR; Oct 2014 9 4 6 14 25 3 




Oct 2014 9 4 6 15 25 3 




600057-DP Darak,CMR; Oct 2014 9 4 6 16 25 3 




Oct 2014 9 4 6 16 25 3 
600046-DP Darak,CMR; Oct 2014 9 4 6 16 25 3 
600060-DP Darak,CMR; Oct 2014 9 4 6 16 25 3 
600055-DR Darak,CMR; Oct 2014 9 4 6 16 25 3 
600041-DP Darak,CMR; Oct 2014 9 4 6 16 25 3 
600054-DP Darak,CMR; Oct 2014 9 4 6 16 25 3 
600069-DP Darak,CMR; Oct 2014 9 4 6 16 25 3 
600055-DP Darak,CMR; Oct 2014 9 4 6 16 25 3 
600067-DP Darak,CMR; Oct 2014 9 4 6 16 25 3 
600065-DR Darak,CMR; Oct 2014 9 4 6 16 25 3 
600050-DP Darak,CMR; Oct 2014 9 4 6 16 25 3 
600057-DR Darak,CMR; Oct 2014 9 4 6 16 25 3 
600040-DP Darak,CMR; Oct 2014 9 4 6 16 25 3 
600060-DR Darak,CMR; Oct 2014 9 4 6 16 25 3 
600061-DR Darak,CMR; Oct 2014 9 4 6 16 25 3 
600065-DP Darak,CMR; Oct 2014 9 4 6 16 25 3 
500291-APW Blangoua,CMR; Oct 2014 9 4 6 16 25 3 
600045-DP Darak,CMR; Oct 2014 9 4 6 16 25 3 
600047-DP Darak,CMR; Oct 2014 9 4 6 16 25 3 
600061-DP Darak,CMR; Oct 2014 9 4 6 16 25 3 
600069-DR Darak,CMR; Oct 2014 9 4 6 16 25 3 
600043-DP Darak,CMR; Oct 2014 9 4 6 16 25 3 
600053-DR Darak,CMR; Oct 2014 9 4 6 16 25 3 
600067-DR Darak,CMR; Oct 2014 9 4 6 16 25 3 
600068-DR Darak,CMR; Oct 2014 9 4 6 16 25 3 
30B Bourrha, CMR; June 2014 9 4 6 17 23 1 






Table 3.3: Number and percentage of initial V. cholerae isolates differing at each loci 
 
No. of isolates 
No. (%) of isolates differing at at each loci 
Large-chromosome loci Small-chromosome loci 
VC0147 VC0437 VC1650 VCA0171 VCA0283 
Overall (82) 8 (9.75) 2 (2.4) 7  (8.5) 13 (15.6) 9 (11.0) 
Cameroon (66) 5 (7.6) 1 (1.5) 2 (3.0) 8 (12.1) 6 (9.1) 
Isolate matches crude 
specimen (16)** 0 0 0 1 (5.9)
¥ 0 
      
**Note: One isolate was 01 dipstick negative in contrast to the crude specimen which was 01 dipstick positive. PCR 
verified this isolate was a non-toxigenic V. cholerae non 01 isolate; the colony morphology may not differ from that 
of a toxigenic V. cholerae 01, signifying that this was a mixed culture and therefore would not match the 01 crude 
specimen.  Since the correct V. cholerae 01 isolate was not sent as an 01 positive to be compared for sequencing it is 
not included here. 
¥ One isolate (600068) differed from its crude specimen genotype at the 4th locus, potenitally signalling that the 
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 The World Health Organization supports use of oral cholera vaccine (OCV) in developing 
countries with endemic cholera.  The current supply and production capabilities, however, 
for OCV are not sufficient to vaccinate entire nations.  Therefore, cholera-endemic 
countries must make decisions about use of OCV in the highest risk areas.  We present a 
rapid assessment tool that uses retrospective national, regional and sub-regional cholera 
surveillance data and geographic distribution of risk factors to identify high-risk areas of 
the country where OCV use can be targeted. 
Methods and Results 
 The assessment begins by determining the cholera incidence rate at a provincial level.  The 
incidence and mortality rates are adjusted for missed cases and deaths by extrapolating 
rates from recently published active case finding studies.  If more localized rates are needed 
further assessment of cholera incidence and risk is conducted at the district level.  If district 
level case and mortality data is available, the incidence and mortality rates are determined 
and adjusted for missed cases and deaths to differentiate districts with low, medium and 
high risk of cholera.  If case and mortality data is not available or is insufficient to 
differentiate high risk areas at the sub-provincial level, risk can be determined through a 
weighted risk factor approach to identify risks of low, medium and high risk of cholera.  
Kenya was the case study for the development of the cholera RAT, evaluating surveillance 
data from 1997 through 2010.  Using both detailed surveillance data at the district level as 
well as the weighted risk factor approach, several high risk areas were highlighted 





 The pilot testing of cholera RAT in Kenya highlights the importance of the 
weighted risk factor  approach; given current vaccine availability MoH’s or other Public 
Health leaders interested in vaccination will have to use a targeted approach to most 
strategically use vaccines allotted.  In Kenya, the RAT highlighted several key areas of risk, 
including the area of Turkana whose provincial level rates were not considered in the high 
risk category, highlighting the importance of working from a national level down to sub-
province or even sub-district levels.  The cholera RAT will continue to be refined as it is 
tested in further cholera endemic countries; however this study demonstrates the 
advantages of this simple tool using locally available data in conjunction with national 
cholera disease rates to better understand the cholera disease burden for cholera vaccine 

















 The World Health Organization recommends use of oral cholera vaccine (OCV) in 
countries with endemic cholera, or in areas at risk for outbreaks of cholera (1).  OCV use 
is recommended in conjunction with other cholera prevention and control strategies. 
Dukoral, a killed V. cholerae (01) vaccine with a non-toxic B subunit component was the 
first oral cholera vaccine to be prequalified by the World Health Organization (WHO).  In 
studies conducted in Bangladesh and Peru in the 1990’s, Dukoral was found to have high 
short-term protection (85%) and a two year combined protection of 60% (2).  A modified, 
bivalent killed oral cholera vaccine, Shanchol, was subsequently prequalified by the WHO 
in 2011 (3). Shanchol contains both V. cholerae 01 and V. cholerae 0139 strains, and its 
safety and efficacy has been assessed in a large scale randomized control trial in Kolkata, 
India.  It has been shown to provide 67% protective efficacy at two years of follow-up (4), 
66% protective efficacy at three years of follow-up (5),  and most recently, a sustained 5-
year protective efficacy of 65% (2).  In addition to the initial safety and efficacy studies 
conducted on the vaccines; studies have been conducted to assess the feasibility and effects 
of a large-scale vaccination campaign in multiple African settings.   
Dukoral demonstrated protective efficacy in two large mass-vaccination campaigns in 
Mozambique (2004) (6) and in Zanzibar (2010), with the campaign in Zanzibar 
demonstrating both direct and indirect (herd) protection (7).  In 2012, Shanchol was finally 
deployed for use in Haiti in the midst of fighting a cholera epidemic that was first detected 
in October 2010. The vaccination campaign in Haiti reported high coverage rates up to 
92.7% in Bocozel and 2-dose completion rates >90% in both Grand Saline and Bocozel 




implemented in Guinea; with one-dose coverage of 92% in Boffa and 71% in Forecariah.  
2-dose completion coverage was slightly lower at 68% in Boffa and 51% in Forecariah (9).  
Follow-up studies in both countries have demonstrated that large-scale vaccination 
campaigns are feasible and acceptable during outbreaks, reflected by high acceptance rate 
and high population coverage in both urban and rural settings (8, 10).  
Despite its proven ability to reduce cholera risk, OCV is not widely used.  One reason 
for this is that the supply of OCV is limited worldwide.   In 2010, Waldor et al published 
a perspective piece on the need for an OCV stockpile, at the time of publication there were 
only 400,00 doses of Shanchol and Dukoral available for shipment (11). In 2013, the WHO 
began the initiative to create a stockpile of 2 million doses of OCV.  In the same year, the 
GAVI alliance promised further support to increase the stockpile to 20 million doses by 
2018 (12). Even as the stockpile is built and maintained, a recent estimate of the global 
burden of cholera estimated that 1.4 billion people are at risk for cholera in endemic 
countries (13), further highlighting the need for increased vaccine production.   With the 
current limited supply of OCV, cholera-endemic countries interested in OCV use are likely 
unable to vaccinate their whole country.  In deciding where to introduce OCV, ministries 
of health must identify regions of the country with the highest cholera risk over the next 3-
5 years.  In countries with sensitive surveillance for cholera over multiple years, historical 
incidence of cholera by region can be used to predict where cholera will most likely occur 
in the future.  Few countries have such surveillance, particularly in Africa, which has 
become the continent accounting for the majority of reported cholera cases worldwide.  In 
2012, Sub-Saharan Africa reported 71% of cholera cases and 86% of cholera deaths, 




created to begin population based cholera surveillance in 11 countries, collecting data on 
demography, symptoms and risk factors (14).  Without longitudinal surveillance, countries 
can utilize a risk-based approach to identify areas most likely to experience cholera, such 
as history of past outbreaks, poor water and sanitation infrastructure and distance to nearest 
health facility (13).   
We present a Cholera Rapid risk Assessment Tool (RAT) that uses locally available 
data for use by Ministries of Health, and other interested parties to use as a tool to aid in 
preparing a preventive strategy to the threat of cholera disease.  While the primary focus 
of the tool is to target high-risk areas for OCV use, it can just as easily apply to other 
prevention strategies, such as safe water programs, as well as bolstering of treatment 
supplies and training.  This method uses retrospective surveillance data to calculate 
incidence rates of cholera disease by geographic region, starting at the provincial level and 
working down to sub-provincial/sub-district administrative levels where possible.  The tool 
includes an adjustment for severe cholera cases and deaths not seen in health facilities, 
which is important in many low income countries where healthcare utilization is low, even 
in the setting of severe disease such as cholera (15, 16). The tool also identifies if regions 
and districts have previously surpassed the presumptive threshold of 1 case per 1,000 
persons as a limit for the cost-effectiveness of OCV introduction (17).  Where incidence 
cannot be estimated or where more defined areas of risk are needed to target vaccination, 
district risk factors for cholera are employed to suggest those districts at the highest risk of 
cholera. 
The cholera RAT is not a predictive model, in the sense that it is not intended to predict 




for use in countries with endemic cholera, in which cholera outbreaks occur on a recurring 
basis, either consistently (e.g. Bangladesh, Mozambique coast) or sporadically (e.g. much 
of Africa). The cholera RAT is not applicable to predicting cholera in a region that has 
never experienced cholera in recent years, such as Peru in 1991 or Haiti in 2010; however, 
many of the risk factors included do provide a guide as to what could happen if cholera 
was introduced into a high risk area. Rather, by assessing retrospective cholera disease 
burden data, the cholera RAT can suggest where cholera has historically occurred in a 
country and if rates have reached levels high enough for the ministry of health to consider 




4.3.1 Overview of Cholera Rapid risk Assessment 
 
 The Cholera Rapid risk Assessment Tool focuses initially on regional level data, 
beginning with a broad approach to collate data to determine cholera disease burden.  
Regional level data may be more readily accessible; however, there are circumstances 
where there may be no interest in the cholera disease burden at this level.  One example 
may be that there may not be sufficient support, to include vaccine supply, to target an 
intervention on such a large scale.  Another example may be that there is knowledge that a 
specific district or sub-region may be of interest for analysis.  While the RAT is adaptable 
to specific settings, analysis of regional and then district level data, systematically, may 
highlight areas of risk that were not previously realized and further enhance cholera control 
efforts in the country. Data sources providing information needed for the cholera risk 




(IDSR) reports in participating African countries, or disease-specific line lists collected at 
a regional, district or sub-district level detailing cases and deaths.  Care should be taken to 
select the most complete reports with consultation and guidance from the Ministry of 
Health (MoH).  Where possible, reports should be collated to provide the most complete 
case and death count.  Due to the uncertain nature of cholera outbreaks in areas such as 
sub-Saharan Africa, we hope to capture a minimum of five years of data.  Analyzing a 
minimum of five years provides information on whether the disease is endemic in the 
country/province/district based on WHO definitions of more than 3 outbreaks in five years 
(18), as well as providing information to compare periods or years when cholera was 
present as compared to those when there was no cholera; providing a better understanding 
of the risk in the area of investigation. 
Figure 4.1 presents a flow diagram outlining the methodology encompassing the 
cholera RAT and its recommendations.  
Step 1: Collection of retrospective counts of cholera cases and deaths at 
Regional/Provincial level.  This is accomplished by working with Ministries of Health and 
Regional Health facilities to collate the aggregated case data by region or province.  
Step 2.  Calculation of regional incidence rates of reported cholera cases.  Census data 
should be obtained to get the regional denominators for the years for which cholera data 
is available.  Population projections might be needed for years in which census data is not 
available, and population growth rates are usually available from census data.  The number 
of reported cholera cases is divided by the population number to get the rate of cholera 




Step 3a and 3b:  Adjustment for cases/deaths not reported to MOH.   To account for 
cholera cases not captured by surveillance, the percentage of cholera cases (Step 3a) and 
deaths (Step 3b) that are not reported, including persons who did not seek care at a medical 
facility, should be estimated.  If possible, local data on health utilization during cholera 
outbreaks should be used to estimate the percentage of cases not seeking care. In a recent 
publication, results from Health utilization surveys were used to adjust surveillance 
estimates of pneumonia, allowing for more accurate estimates of case burden (19).  Care 
should be taken to use the same criteria and definition of cholera as used for reported 
cholera cases in health facilities, in order to ensure that cases of equal severity are counted 
rather than mild or asymptomatic cases. Existing health utilization data on syndromic 
diarrhea in a non-cholera setting (e.g. DHS) is not appropriate for cholera as it is a rare 
event and therefore it may not be frequent enough to be detected in a DHS survey.  If 
health utilization data is available for cholera, the number of cases of cholera reported 
from surveillance should be divided by the percentage of all cholera cases that sought care 
at a health facility as ascertained from a health utilization survey.   If health utilization data 
is not available, other data sources that should be considered include WHO reports, IDSR 
reports or separate line lists at regions and district level.  Where possible, reports should 
be collated to provide the most complete count.  The selection of the most complete reports 
should be made in consultation with the MoH. 
Because health utilization data during cholera outbreaks will be rarely available locally, 
and it may be difficult to supply sufficient line-list or IDSR reports depending on the 
location; the base-case algorithm uses estimates from the literature.  The suggested 




in an active case finding study conducted by Shikanga et al.  During a period of civil unrest 
in 2008, western Kenya suffered a cholera outbreak.  The Ministry of Health conducted a 
case finding study in the three districts reporting the highest number of cholera cases.  The 
case finding included interviewing administrative persons and sub-chiefs of the various 
districts, interviews of any households reporting cases plus other households of reported 
interest.  The study reported that there were 271 of 396 cholera cases (46%) not reported 
and that the active case finding found 30 missed deaths and an adjusted case fatality rates 
(CFR) of 24% as compared to the MoH reported 15 deaths and CFR of 5.5% (20).  In the 
absence of more country specific data, the RAT will apply the rate of (46%) missed cases 
and (24%) missed deaths to adjust the total number for disease burden calculations. 
Step 4. Calculation of regional incidence rates of total cholera cases.  In this step the 
numerator is adjusted to account for the unreported cholera cases calculated in step 3.   As 
in step 2, the incidence is calculated using the population denominator.  At this point, the 
annual calculated incidence by region can be compared to a putative threshold for OCV 
vaccination of 1 case per 1000 persons.  The threshold for vaccination is based on an 
analysis exploring the cost effectiveness of oral cholera vaccine implementation in 
endemic areas.  Assuming costs representative of estimates for Bangladesh, the model 
found that if the vaccine cost is approximately 1 USD and the expected incidence is 1 per 
1000 persons or greater, than the introduction of vaccination should be considered (17).  
The cut off of an incidence of 1/1000 is applied to the assessment in the cholera RAT 
analysis to identify areas of increased or high risk where authorities or public health 




With the current level of availability of OCV, a regional population (e.g. Province) is 
likely too large to fully vaccinate, a further breakdown of the risk at smaller administrative 
levels may be warranted.   If there is sufficient supply of OCV available and the MoH 
determines that vaccination is warranted at the regional level based on number, the cholera 
RAT investigation may stop at step 4; otherwise the investigation may proceed to step 5.  
Step 5a Calculation of sub-regional incidence rates of total cholera cases.  Step 5a 
involves assessment of the number of cholera cases at the sub-regional level where data is 
available for review.  The procedure in this case is similar that that undertaken at the 
regional/provincial level in steps 1-4. Data at a sub-regional/district level is gathered by 
working with the respective district level Ministries of Health facilities to collate the 
aggregated case data by sub-region or district.  The data source for sub-regional data might 
or might not be the same as for regional data. 
Step 5b is the alternative and/or additional option to assess sub-regional risk of cholera 
if Step 5a was not possible due to lack of available cholera surveillance data or if the data 
is not sufficient to identify the desired target population.   Risk is assessed by a cumulative 
score for the sub-region according to the presence of several key risk factors for cholera.  
The weighting system is based on the Delphi consensus method.  The Delphi is based on a 
multi-stage iterative process in which a panel of experts anonymously provides responses 
to a structured questionnaire. The process is repeated for 2 or more rounds, after each round, 
the statistical analysis of the group’s collective opinion is used to form the subsequent 
round of questionnaire.  This process is repeated in order to achieve a consensus among 
the experts (21).  A panel of 20 experts was asked to assign weights to cholera risk factors 




experts, highlighting risk factors associated with high risk, medium risk and low risk of 
cholera. The risk factors are detailed in Table 4.2.  The list includes various factors of 
importance when considering impending cholera risk.  The risk factors are listed according 
to importance for consideration of cholera risk.  The key risk factors to consider in an 
endemic setting are risk factors 1 through 9; these risk factors were rated the most important 
among our panel of experts in the Delphi survey with minimal discord in their scoring.  The 
remaining risk factors of low to medium ranked importance should be considered if the 
data is readily available.  The risk score assigned to each risk factor is based directly on the 
Delphi results.   
The first factor to consider is the incidence rate calculated in steps 1 through 5.  Disease 
burden is the most direct measure of risk that can be applied.  Evidence of this risk is 
demonstrated in the disease burden of endemic countries such as Bangladesh and India 
with annual cholera outbreaks, as well as endemic African countries such as Zimbabwe 
and Mozambique, which have demonstrated, repeated outbreaks since cholera first 
appeared in Africa (6, 22).  The highest risk is in areas with rates of disease greater than 2 
per 1,000 persons, heightened risk where vaccination should be considered include areas 
with incidence rate of 1-2 per 1,000 persons.  The risk weights assigned are based on 
whether the district has reached the previously described incidence rate threshold of 1 per 
1000. 
Risk Factor 2 is the occurrence of a cholera outbreak within the previous 5 years to 
include the number of outbreaks during this time.  Populations with a history of cholera 
outbreak, particularly more than one outbreak, is a strong predictor of another outbreak 




steps in the RAT, including collation of MOH reports, WHO reports, line lists and IDSR 
reports, if available.  Previous presence of a cholera outbreak is the strongest risk factor 
considered, therefore it is awarded the highest weight.  The greatest risk would be in an 
area which is considered endemic, as previously stated, defined as having more than three 
outbreaks in the previous five years (18), Therefore the weighting assigned is tiered: a score 
of 0 for no previous outbreaks, a score of 2 for 1-2 outbreaks in the previous 5 years, and 
a score of 4 for 3 or more outbreaks in the previous 5 years (an endemic area).   
Risk Factor 3 is the consideration of outbreaks in neighboring areas.  Cholera has 
historically spread from country-to-country through travelers; the first six pandemics 
spread globally from the Indian subcontinent.  In August of 1970, the seventh pandemic 
spread to West Africa in Guinea.  Figure 4.2 shows the route of spread of the disease upon 
entry.  The disease spread country-to-country from Guinea to Sierra Leone, Liberia, Cote 
d’Ivoire, Ghana, Togo, Benin, Nigeria and Cameroon successively between September 
1970 and February 1971 (24).  The same transmission patterns continue to be seen today, 
therefore neighboring countries as well as regions within a country must be considered 
when assessing cholera risk.  The risk weight is assigned considering areas surrounding a 
district or sub-district.  If there has been no cholera in the current year in the surrounding 
area then a risk score of zero is applied; if there has been cholera confirmed in neighboring 
areas in the past year that do not share a direct border the risk score is; and if there has been 
cholera confirmed in neighboring areas which share a common border then the risk score 
is 7. 
Risk factor 4 is the distance to a health facility. A 2005 study in Vietnam demonstrated 




those living further away (25).  Distance to health facilities likely plays a role in health care 
utilization, in both mild cholera cases and most especially in severe cholera cases, when 
patients may not have adequate time or transportation to reach care.  The best data for use 
in the RAT assessment would be measured by surveying how far the population must travel 
to reach a health facility.  In the event that such a comprehensive survey does not exist, or 
if GIS measurements of households and facilities are not available, a proxy for this measure 
is to assess the health facility density per district.  This World Health Organization (WHO) 
health infrastructure indicator can be considered a risk factor (26).    The WHO states the 
target for this indicator is to have 2 health facilities per 10,000 persons.  A risk score of 2 
is assigned to districts/sub-regions with less than 2 health facilities per 10,000 persons.  A 
risk score of 1 is assigned to districts/sub-regions with 2 or more facilities per 10,000 
persons.   
Risk Factors 5 and 6 are access to safe water source and access to improved sanitation, 
respectively.  Inadequate access to clean water and proper sanitation are also considered as 
potential indicators of cholera risk.  Several studies have shown that access to improved 
water can significantly reduce the number of cholera cases (23, 27). Esrey et al showed 
that sanitation and hygiene reduced the risk of diarrhea morbidity and mortality, with 
diarrhea mortality reduced to the greatest extent by flush toilets than latrines (28).  A 2010 
meta-analysis evaluating the effect of water, sanitation and hygiene for the prevention of 
diarrhea proposed a 17% and 36% diarrhea risk reduction with improved water quality and 
excreta disposal, respectively (29). The risk can be quantified by accessing data on the 
percent of the population using protected water sources and improved sanitation.   The data 




and non-improved water sources and improved and unimproved sanitation (30).  The 
current risk score of 7 is applied if 60% or more of the district’s population uses water 
sources characterized as unimproved, if 30%-60% of the population use unimproved water 
sources the risk score is 4, and if less than 30% use unimproved water sources the risk 
score is 1.  The weighting similarly applies for to the percent of the population using 
unimproved sanitation in the district.  
The case-fatality rate is the 7th risk factor considered of high importance.  Case fatality 
rates should be less than 1% when cholera is treated promptly; however the high mortality 
rates registered throughout Africa in the last decade highlights a lack of appropriate access 
to health care (20, 31).  The case fatality rate is adjusted as described in step 3a/3b, and the 
average case fatality rate for the time period of 1999-2010 in Kenya is weighted based on 
the Delphi assigned weight of 9.  If the CFR is <1%,the risk score assigned is 1, if CFR is 
between 1-2% then the risk score is 4, and if CFR is >=2% the risk score assigned is an 8. 
Risk factor 8 is the use of oral rehydration solution (ORS).  This risk factor is an 
important measure of health care access as well as knowledge of treatment of diarrheal 
disease and dehydration.  The use of ORS is likely associated with mortality rates given its 
pivotal role in reducing CFRs.  This was first clearly demonstrated in the early 1970’s when 
a severe cholera epidemic broke out among Bangladeshi refugees in West Bengal, India.  
When intravenous fluids ran out, the use of ORS was employed by family to treat more 
than 3,000 patients, reducing the mortality rate from 30% to 3.6% (32).  The method was 
shown to be a simplified, low cost method not only for health-care workers, but family 
members to treat diarrheal patients (33).  The data for this risk factor can be found working 




with diarrhea is a common measure used in DHS surveys.  If more than 75% of people are 
administering ORS for diarrheal disease, the risk score is 0,  if only 25-75% of people are 
administering ORS for diarrheal disease treatment the risk score is 4, and if <25% are 
administering ORS the risk score is 7. 
Risk factor 9 accounts for the presence of vulnerable populations.  Cholera is known to 
be a public health problem among displaced populations due to lack of or insufficient clean 
water and proper sanitation, among other factors.  This risk factor accounts for the presence 
of refugee, internally displaced persons (IDPs), slums or tribal communities in the sub-
region being evaluated.  It also allows accountability for recent natural disasters, such as 
flooding or earthquakes, and for poor access to health care as a result of terrain or 
transportation issues.  These vulnerable populations have been shown repeatedly to have a 
risk of cholera outbreaks, including IDPs and refugees in Kenya (34)  and the on-going 
epidemic in Haiti (35) .   The data for this risk factor can be found through working with 
the Ministry of Health.  The risk score is 1 if one vulnerable group is present; .the risk score 
is 3 if 2 vulnerable groups are present and the risk score is 6 if 3 or more vulnerable groups 
are present in the district. 
The remaining risk factors were weighted as medium to low level important for cholera 
risk.  These risk factors include population density, proximity to large water bodies, 
socioeconomic status (SES) disparity or poverty, Under-five mortality rate, water-
switching, cultural behaviors and environmental factors.   The evidence for risk, risk weight 
factor and cut-offs for these risk factors are further detailed in table 4.2.  If the data for 
these risk factors are available, they should be incorporated into the RAT for improved 




Population density and overcrowding have been identified as risk factors for cholera in 
many studies (36-38).  This risk factor has been linked to the lack of sanitation in 
overcrowded and poverty stricken areas, or potentially because living in close proximity 
decreases the distance needed for transmission (37).  This data can be found through census 
data, and the risk weight is assigned based on a weight of 6 incrementally assigned per 
quintile. 
Several studies have found that proximity to estuaries (39, 40) as well as lake areas 
(41), have increased risk of cholera.  The data for the risk due to proximity to large water 
bodies including lakes or estuaries can be gathered by working with the Ministry of Health 
for maps of the country including water bodies and district markings. The risk score is 
Score is 1 if there is less than 1 water body in the district, 3 if 1-2 water bodies and a risk 
score of 6 if there are more than 2 water bodies. 
The risk factor for SES disparities takes into account the fact that cholera is often 
associated with poverty, where safe water and sanitation are lacking. Socioeconomic 
disparities are an important component of cholera risk as cholera has been shown to be 
more prevalent in low-income countries as compared to middle or high income countries 
(42).  The risk associated with poverty and socioeconomic status (SES) may be measured 
in different ways depending on the data available in each country.  The percent of the 
population living below a country’s poverty line can be extracted from DHS surveys or 
census information.  If less than 30% of people in the district are measured to live in poverty, 
the risk score is 0, poverty levels between 30-60% have a risk score of 1, and > 60% has a 




Under-five mortality is the probability per 1,000 that a newborn baby will die before 
reaching age five, if subject to current age specific mortality rates. Under-five mortality 
rates are reported regionally/provincially for DHS surveys.  In the event that a country has 
sub-regional data for under-five mortality rates, these should be applied.  Otherwise, under-
five mortality rates for the region are applied to each district within the region, with the 
understanding that under-five mortality is the result of a wide variety of inputs such as 
access to health care, poverty, water and sanitation, among other variables (43) and will 
provide a more comprehensive understanding of each district in conjunction with district 
level indicators for these other variables.  A risk score of 1 applies to a district with a U5M 
of < 50 per 1,000; a risk score of 3 applies to a U5M of 50-100 per 1,000, and a risk score 
of 5 applies to a U5M of >100.  
Health care infrastructure, accessibility and supplies are considered in the risk factor 
for local health facilities ability to set up a Cholera Treatment Center (CTC).  This risk 
factor considers the foundation of knowledge and preparedness at a district level to support 
a cholera outbreak, including the ability to set up cholera treatment center and oral 
rehydration units as separate wards, the presence of supplies to treat cholera (ORS, ringer 
lactate and IV lines), and the presence of healthcare staff trained to support cholera patients.  
The weighting is based on incremental levels of knowledge and preparedness; Local health 
facility trained as CTC is a risk score of 0; if the local health facility has been given basic 
guidance but not regularly practiced with a plan to implement is a risk score of 3, and if 
the local health facility has been given no training the risk score is 5. 
The risk factor accounting for a district being a high transit area is important due to the 




circulation and transmission of cholera in the surrounding urban area (44, 45).  This risk 
factor weighs whether a district has a large urban area, whether transport is readily 
available, including good roads, train or airplane, and whether there is a busy marketplace 
in the district or area.   The risk score is weighted based on the incremental amounts of 
transit in the district;  if 1  transit area is present the risk score is 1;  if 2 transit areas are 
present the risk score is 3; and if 3 or more transit areas are present in the district the risk 
score is 5. 
A rarely considered cholera risk factor that is rarely considered is a measure of “water-
switching”.  Water Switching is based on the risk associated with an unstable water supply.  
In areas of conflict, natural disaster, poverty where there are not a regular water supply 
(among others) people may be forced to change water supplies to unsafe sources.  
Insufficient infrastructures for safe water is recognized as a major factor that contributes to 
cholera outbreak (46), and water switching is one way to measure this risk. Most countries 
will not have surveyed for this information, and in that even rainfall measures can be used 
as a proxy.  The data can be collected from the national meteorology department.  The 
scoring of this risk factor will depend on if there is a water switching survey available or if 
rainfall data is used.  Rainfall data is dynamic as the survey data will be static.  In the event 
that a survey has been conducted to assess water switching, risk score is based on level of 
risk to include how many times they had to switch, why the switch occurred and if the 
switch was to a more at-risk water source.  In the event that water switching data is not 
available, rainfall can serve as a proxy (risk factor 18) with the idea that a significantly 
different (over or under-abundance of rain) would lead to increased cholera risk and 




Cultural behaviors such as hygienic behaviors, funeral practices, large social gatherings 
and literacy, are grouped into one risk factor.  This blended risk factor is to allow for 
adjustment for these practices in a community that have been linked to increased cholera 
risk (47, 48).  This data will be found at the district or sub-district level and may be more 
difficult to gather for a rapid assessment.  The weight risk assigned is a total of 4, based on 
the number of these “at-risk” behaviors practiced regularly in the community at the district 
or sub-district level. 
Studies have continued to demonstrate the relationship between elevated temperature 
and increased cholera risk (49, 50), given appropriate transmission conditions.  The data for 
the risk associated with temperature can be obtained by working with the countries 
meteorological department.  The risk score is based on average temperature in the previous 
two months; if the temperature is higher than the average the risk increase.  We weight the 
risk based on statistically significant difference in temperature: the risk score is 0 if the p 
value is greater than 0.1, the risk score is 1 if the p-value for the increase in temperature is 
between 0.05-0.1, and the risk score is 2 if the p-value of the increase in temperature is less 
than 0.05. 
In addition, if a country does not have data for specific risk factors in the RAT, this 
does not have to impede the analysis.  The analysis can be done based on the risk factor 
data available.  The total risk per district will be based on the risk points tallied per the total 
risk point potential for the considered risk factors.  Districts or sub-regions are stratified 
into low, medium and high risk based on their risk score.  Low risk areas are areas where 
no vaccination is warranted; assigned to areas with incidence rates less than less than 0.5 




areas with incidence rates between 0.5 -1 per 1000 and/or risk scores between the 2nd and 
4th quintile.  In these areas the cholera risk is below the threshold for vaccination, however 
due to the presence of cholera previously or reasonable risk factors cholera interventions 
are recommended to include enhanced cholera surveillance, WASH interventions and 
cholera prevention education.  High-risk areas are areas where the cholera incidence rate 
is greater than 1 per 1000 and/or the risk score is in the top quintile of risk score.  In this 
highest quintile of risk, where available and feasible, the use of OCV in addition to other 
cholera interventions should be considered. 
 
4.3.2 Study Site 
 
     Kenya has reported regular epidemics of cholera since shortly after the disease first 
appeared in Africa in 1971 (51).  Cholera surveillance in Kenya is monitored regularly as 
part of the Integrated Disease Surveillance and Response (IDSR) program, which is 
managed by the Division of Disease Surveillance and Response within the Ministry of 
Health of Kenya.  Weekly reports of reportable diseases, including line-lists of cases and 
deaths, are reported from district health facilities to the central MOH in Nairobi.  The 
program was adopted to include cholera disease reporting in 2000 (51); Kenya has 
surveillance data that can be extrapolated for use in assessing the cholera RAT, with 
assumptions being made in the years just prior to adoption of the IDSR program as well as 
in the early years of its incorporation. The time frame included in the Kenya analysis is 
from 1997 through 2010, however, the 1997-1998 data was not available at the district 
level, only the provincial level.   Therefore, we include information from 1997-98 as much 




were identified.  Kenya has modified their districts and county level designations multiple 
times in the period analyzed; since the majority of the data utilized in the analysis is from 
the period when there were 69 districts we present the results according to the districts that 
existed as of 2007 (52).      
Step 5b and the subsequent pathway to risk assessment was also evaluated in the Kenya 
analysis to determine the value of the risk factor approach in targeting cholera risk at 
district level.  To further build the tool we worked with the personnel at DDSR, as well as 
utilizing Kenya’s open source data to extrapolate parameters for relevant cholera associated 
risk factors at the district level.  The risk factor for previous cholera outbreak was tabulated 
using the line list data provided by DDSR.  The information to assess the health facility 
density, as a proxy for distance to health facility was abstracted from the 2009 Kenya 
census data on health facilities per district and sub-district  (53).  Water and sanitation risk 
factor data was based on the percent of the population using unprotected water sources and 
unimproved sanitation by district level, derived from the 2009 Kenya census data and 
published on Kenya’s open data site.  Poverty/SES disparities risk was also abstracted from 
the Kenya 2009 census information utilizing poverty rates by district (53).    Under five 
mortality rates and ORS use for Kenya are available in the 2009 DHS Survey, however 
this data is only available at the provincial level.  Broad assumptions were made applying 
provincial level rates to each district.   
4.4 Results 
 
From 1999-2010, cholera was reported during at least one year in all seven 
provinces in Kenya (Figure 4.3a and b).  When adjusting the rate for health utilization, in 




one province reaching the threshold in 2007 (Northeast) and 2009 (Eastern, Figure 4.3a 
and 4.3b). The total number of cholera cases during the entire period was greatest in the 
Eastern Province (n=9440), followed by Coastal Province (n=6400) and Rift Valley 
province (n=6338).  The highest adjusted case rate in any province was 2.67 per 1000 
persons in 1999.  If the threshold were lowered to 0.5 cases per 1000, then five provinces 
would have met the threshold during the study period, though only Eastern and 
Northeastern Provinces would have reached this lower threshold in more than one year.  
Figure 4.4a-h shows the annual rate of cholera for all districts in Kenya, divided by 
province.   Although only three provinces reached the 1 per 1000 threshold, many more 
districts reached the threshold in at least one year – namely 24 of the total 69 districts 
(Table 1). Of these districts, seven districts reached the threshold at least two times.  
Although the district level data for 1999-2000 was estimated, it is likely that at least one 
district in Nyanza Province might have reached the threshold three times.  The districts that 
reached the threshold more than once fall into two broad ecologic zones – the arid, sparsely 
populated regions of Northeastern Kenya (Isiolo, Tharaka, Mandera, Wajir) and the 
seasonally wet districts bordering Lake Victoria in the western part of the country (Kisumu, 
Nyando, Suba).      
Applying the risk-based approach at the district level (Step 5b) revealed a range of 
risk scores from 15 in Taita Taveta District in the Coast Province (low-risk) to 54 in Moyale 
District in the Eastern Province (high risk) (Figure 4.5a).  These results do align with the 
incidence rates, as Taita Taveta did not report a single case during the time period analyzed, 
classifying as low risk; while Moyale District had an extremely high incidence rate in 1999 




level for all risk factors, therefore the cumulative risk weight was based on the data 
available.  Figure 4.5a illustrates the cumulative weighted cholera risk results by District 
in Kenya, demonstrating that within a Province, the risk by district varies.  The risk weights 
were also compared by scoring based on the highest value among the districts.  This score 
was weighted set as the highest risk weight, and the remaining scores for the district values 
were weighted in comparison to this score.  These results are shown in Figure 4.5b.    The 
two scoring systems highlighted similar high risk districts; if the top five percent for risk 
score are considered both scoring methods included Marsabit, Moyale and Turkana 
districts.  There was one difference where the weighting based-on cut off weighted Suba 
district in the top 95%, weighting by scaling weighted Isiolo in the top 5%.  The results of 
the risk-based approach falls in line with the prediction of cholera thresholds at 1 per 1000 
if the highest risk areas are compared to the results in Table 4.1; all districts in the top 5% 
of risk surpassed the threshold of 1 per 1000 in one or more years.  Based on the adjusted 
incidence rate results, the government of Kenya might want to consider the results in Table 
4.1; in which 8 districts were highlighted as having surpassed the threshold of 1 per 1000 
in more than one year.  With the current vaccine shortages, the government is unlikely to 
have access to sufficient vaccines to target all of these districts.  Considering at the risk-
factor based approach, the highest risk districts are further stratified to potentially guide 




The Kenya cholera risk assessment highlights that Government and/or Ministry of 




vaccination and other cholera interventions.  In Kenya, the provincial populations that 
surpassed the threshold of 1 per 1000 were between 1.3 million and 6.1 million persons.  
Current oral cholera vaccine production rates are limited with current production of only 2 
million doses per year, for worldwide distribution (54). Recent initiatives to increase 
production and distribution of oral cholera vaccine will likely increase the availability of 
oral cholera vaccine, however for the current and near future, assessments with case rates 
above the threshold of 1 per 1000 with large base populations will have to target 
vaccination efforts to those at highest risk(12) .    
 The cholera RAT will continue to be evaluated in other endemic countries such as 
Uganda and Nepal.  The beta assessment of the cholera RAT and its tools utilizing data 
supplied by the Ministry of Health of Kenya, among other sources, highlights areas where 
further development is needed.  Given Kenya’s history of surveillance and the fact that it 
has maintained historical records, the data from Kenya highlighted multiple districts or 
sub-regions with a high-risk or above threshold for cholera vaccination consideration.  This 
illustrates that most countries may need to incorporate the use of risk factors for cholera in 
order to target cholera interventions to areas at greatest risk where cholera vaccination 
campaigns are financially and politically feasible. 
The RAT analysis will be used to inform the MOH’s decision to use OCV.  In 
Kenya, several provinces were highlighted to have elevated risk (above the vaccination 
threshold of 1 case per 1000 persons) during the period of analysis, including the coastal 
province, the Eastern Province and the North Eastern Province.  Continued data analysis 
revealed areas at high risk of cholera in specific districts in these provinces as well as others 




at a provincial level did not surpass the threshold of 1 case per 1000 during the time period 
analyzed.  Turkana district in the Rift Valley is an arid area known to be prone to cholera 
outbreaks (51) which surpassed the 1 case per 1000 during the time period, recording 
between 1-3 outbreaks and received a risk score of 43 (high risk).  This highlights the 
importance of working down, from a national level to sub-region, and beyond if needed. 
Advantages of the RAT include that it is a simple tool that utilizes local data in addition 
to nationally reported rates while engaging the Ministry of Health.   In comparison to 
setting up a prospective surveillance study to determine the cholera risk and incidence at 
local levels, the RAT provides an estimate of this information in a very short period of time.  
Similarly to cholera disease risk and the implementation of oral cholera vaccination, a 
major hindrance in the development and deployment of a haemophilus influenza type b 
(Hib) vaccine was the lack of understanding of Hib disease rates in developing countries.  
A Rapid Assessment tool was developed to estimate the rates of Hib and pneumonia within 
7- 10 days using retrospective local data, and has since been used in developing countries 
in sub-Saharan Africa, the Middle East and Asia (55).  The process of gathering the data 
for the RAT engages local policy makers and the Ministry of Health.  By working closely 
with key health and political personnel, the RAT can provide evidence necessary for policy 
makers to implement the use of OCV as an intervention for cholera outbreaks.  
The RAT has several limitations.  The successful application of the RAT depends on 
having some surveillance in place during recent history.  If a country’s surveillance is poor, 
then the RAT results will also be of poor quality.   Cholera surveillance programs such as 
those being implemented by Africhol will continue to strengthen the RATs applicability.  




hopefully work in conjunction with prediction models currently being developed.  The 
vaccination threshold of 1 cholera case per 1000 persons is an estimate based on cost-
effectiveness of the vaccine.  If the demand for the vaccine increases, increasing production 
and reducing the cost of the vaccine, this threshold could change.   The current adjustment 
for missed cases and deaths is based on limited evidence, more health utilization surveys 
in cholera outbreak settings are needed to improve understanding of health care seeking in 
different settings. 
 In conclusion, the results of the cholera RAT must be considered based on the 
setting in which the assessment was conducted.  The RAT is built to allow for assessment 
even when data availability is limited; however, the quality of the data available will 
influence the strength of the results.  The cholera RAT will be strengthened as it is refined 
through continued use and application in cholera endemic countries.  Until oral cholera 
vaccine becomes more widely available, understanding the disease burden in each country 

































































































































Provinces, grouped by year 1999-2010

















































































































































































































































































































































































































































































































 Table 4.1: Number of Districts above threshold 1/1000 from 1997-2010 
# of Districts above Threshold (1/1000) from 1997-2010 
Province >1 Year 1 Year 0 Years 
Central     All districts 
Coast   
Kwale; Lamu; 
Malindi; Mombasa 
Kilifi; Taita Taveta, Tana River 




Embu; Machakos; Mbeere; Meru 
Central; Meru North; Nithi (Meru S.) 
North 
Eastern 
Mandera-2; Wajir-2   Garissa 





Bondo; Gucha (S. Kisii); Homa Bay; 
Kisii Central; N. Kisii (Nyamira); 
Rchuonyo 




Baringo; Bomet; Keiyo; Kericho; 
Koibatek; Laikipia; Nakuru; Nandi; 
Narok; Trans Mara; Trans Nzoia; 
Uasin Gishu; Buret 
Western     All districts 
*Actual Distribution of cases in Kisumu & Migori is unclear for 1998.  Assumptions made that 50% 
occur in each distribution. ǂ The breakdown of the 1997 outbreak is unclear, however it was noted to 
have occurred predominately in Kisumu area of Nyanza so this is the only district allotted an outbreak 








Table 4.2 Risk Factors Weighting Approach 






1 Incidence Rate 




Endemic countries have 
demonstrated trends in repeated 
outbreaks 
(6, 22) 
2 previous cholera outbreak 
0 outbreaks=0; 1-3 
outbreaks per 5 years = 
4; >3 outbreaks per 
5years = 8 
8 
Populations with a history of cholera 
outbreak, particularly more than one 







Cholera not reported in 
surrounding areas=0, 
cholera reported in 
neighboring areas but 
those sharing a direct 
border = 3, cholera 
reported in bordering 
areas/towns=7 
7 
Historical and current outbreaks 




Distance (hours) to 
the closest health 
facility 
<1 hour=0; 1-4 hours= 
4; >5 hours = 8 8 
Distance to health facilities likely 
plays a role in health care utilization, 
in both mild cholera cases and most 
especially in severe cholera cases, 
when patients may not have 








Weight (1 if >100; 3 if 
50-99; 5 if <50) 5 
The distance from the health care 
provider may have an effect on 
health care utilization. As a proxy 
for distance, we assess the number 
of health facilities per district.  Per 




5 Water Source 
Score is 1 if <2; Score is 
4 if > 2 but < 3; Score is 
7 if >3 
7 
The percentage of the population 
that uses water sources characterized 




Score is 1 if <2; Score is 
4 if > 2 but < 3; Score is 
8 if >3 
8 
The percentage of the population 
that uses sanitation sources 




if CFR is <1%=1, if 
CFR is 1-2%=4, if CFR 
is >=2%=8 
8 
Case fatality rates should be less 
than 1% when cholera is treated 
promptly; however the high 
mortality rates registered throughout 
Africa in the last decade highlights a 
lack of appropriate access to health 
care. 
(20, 31) 
8 ORS use 
If >75%=1;, Rate <75% 
but >25%= 4; if 
Rate<25%=7 
7 
This risk factor is an important 
measure of health care access as well 
as knowledge of treatment of 






If 1 group present=1;, If 
2 groups present=3; if 3 
or > present=6 
6 
1) presence of migrant population, 
internally displaced population, 
slums, or fishing communities 2) 
security and safety concerns, 3) 
frequented by calamities/disasters, 4) 





migrant pop, IDPs, 
slums, or tribal 
communities 












9b Security and safety concerns  7  
 
9c Frequented by calamities/disaster  6  
 
9d 
Poor access to 
health services due 
to terrain/transport 
issues 
 7  
 
10 Population Density 
Based on quintile for 
population Density.  
Quintile 1(lowest 
density)=1; quintile 2 & 
3=2; quintile 5=4; 
Quintile 6=6 
6 
This risk factor has been linked to 
the lack of sanitation in overcrowded 
and poverty stricken areas, or 
potentially because living in close 
proximity decreases the distance 
needed for transmission 
(36-38) 
11 Proximity to large water bodies 
Score is 1 if <1; Score is 
3 if > 1 but < 2; Score is 
6 if > 2 
6 
Several studies have found that 
proximity to estuaries as well as lake 
areas, have increased risk of cholera. 
(39-41) 
11a 
Are there lakes or 
estuaries in the 
district/area? 
   
 
11b 
How many lakes 
or estuaries in the 
district/area? 
   
 
11c 
What is the % of 
the population that 
use the water body 
as their primary 
water source? 
   
 
12 SES Disparity/Poverty 
If Rate<30%=1;, Rate 
>30 but <60%=,3; if 
Rate>=60%=5 
5 
Socioeconomic disparities are an 
important component of cholera risk 
as cholera has been shown to be 
more prevalent in low-income 
countries as compared to middle or 
high income countries 
(42) 
13 U5M Risk Factor WT (<50=1; 50-100=3; >100=5) 5 
Previous studies have shown a 
relationship between high infant 
mortality rates and cholera.  Both 
cholera and high infant mortality 
rates are associated with poor water 
and sanitation and poverty.  The risk 




facility trained as a 
cholera treatment 
center 
Local health facility 
trained as CTC = 0; 
Local health facility 
given basic guidance but 
no clear plan = 3, no 
training = 5 
5 
This risk factor accounts for the 
presence of a health infrastructure, 




Ability to set up 
cholera treatment 
center and oral 
rehydration units 






supplies to treat 
cholera (ORS, 
























15 Transit areas 
if 1  transit area risk 
present = 1;  if 2 risks 
present = 3; if you have 
3 or more transit area 
risks present= 5 
5 
Studies have assessed the 
relationship among high transit areas 
and increased risk of cholera due to 
more dense population but also 
potential for the increased 
circulation and transmission of 
cholera in the surrounding urban 
area 
(44, 45) 
 Is the district area an urban area?    
 
 
Is transport readily 
available, 
including good 












16 Water Switching (rainfall?) 
Score is 1 if <2; Score is 
2 if > 2 but < 3; Score is 
4 if >3 
4 
Insufficient infrastructures for safe 
water is recognized as a major factor 
that contributes to cholera outbreak, 
and water switching is one way to 
measure this risk 
(46) 
 
How often is the 
water source 
changed 
   
 
 Why does the switch occur    
 
 
Was the switch to 
a more at-risk 
water source 
   
 
17 Cultural behaviors 
if 1  SES or cultural 
behaviors present = 1;  if 
2 behaviors present = 2; 
if you have 3 or more 
behaviors = 4 
4 
Cultural behaviors such as hygienic 
behaviors, funeral practices, large 
social gatherings and literacy have 













that involve risk of 
cholera infection 












18 Rainfall (Flooding/drought) 
Risk Score based on p 
value: score is 0 if >0.1; 
risk score 1 if 0.05-0.1; 
Risk Score 2 if <0.05 
3 
Studies have shown that an over or 
under-abundance of rain (flooding or 
drought) can lead to increased 
cholera risk and conditions 
(46, 48) 
19 Temperature 
Risk Score based on 
average temp in 
previous months: score 
is 0 if >0.1; risk score 1 
if 0.05-0.1; Risk Score 2 
if <0.05 
2 
Studies have continued to 
demonstrate the relationship 
between elevated temperature and 
increased cholera risk, given 
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Chapter Five: Conclusions and Recommendations 
 
5.1. Summary of Major Findings 
 
  The findings of this dissertation highlight several new epidemiological and 
laboratory diagnostic tools for cholera surveillance and intervention in low resource 
settings, as well as identifies potential strategies for intervention implementation in 
endemic areas.  There is limited understanding of the true disease burden of cholera in 
many areas globally due to the difficulty and cost associated with confirming suspected 
cases, and even more, the complexities of maintaining regular disease surveillance.  The 
lack of knowledge surrounding disease burden has resulted in limited vaccine production 
in the past, and currently hinders the strategic targeting of the available vaccines and other 
interventions in both reactive and endemic settings.  These simple, affordable, and 
sustainable tools allow for more accurate disease burden estimates that have widespread 
application for furthering understanding of cholera transmission dynamics and guiding 
policy    
5.1.1. Paper I 
 
 There have been minimal attempts to characterize the burden of cholera the Far 
North of Cameroon in spite of recurring outbreaks since the first appearance of cholera in 
Cameroon in the 1970’s.   Paper 1 demonstrated the successful implementation of a 
modified sentinel surveillance methodology in a remote area suffering from security issues 
throughout the entire study period.  In addition to demonstrating early identification and 
confirmation of cases, the presence of surveillance activities in several districts resulted in 




cholera prevention measures, disease confirmation and improved reporting and 
documentation of disease burden information. 
 Paper 1 successfully demonstrated the routine use of the modified dipstick protocol 
in a remote setting with a significantly improved specificity of 99.8%.  These results 
highlight the feasibility of this modified methodology in any setting as well as the 
applicability of low-resource requiring lab diagnostics to improve disease detection and 
surveillance.  Further, the use of readily available laboratory supplies such as gauze and 
water bottles to replace current expensive filtration methodologies not only decreases 
overhead costs but increases feasibility of important environmental surveillance that can 
provide a better understanding of the disease, seasonality and transmission patterns.  
Finally, the novel application of filter paper as a preservation method for specimens for 
confirmation testing by PCR not only reduces laboratory costs by eliminating the need for 
culture as a confirmation and gold standard test, but allows for more advanced molecular 
epidemiology and characterization of disease transmission pathways. 
 
5.1.2. Paper II 
 
 Paper 2 expands upon the findings related to the use of simplified laboratory 
diagnostics in vulnerable and remote field setting.  This study demonstrates that the 
simplified preservation technique of dried filter paper spots, for crude environmental or 
stool samples after Alkaline Peptone Water (APW) enrichment or for the preservation of 
purified isolates for simplified shipping, enables the simplified storage and transport for 
successful molecular characterization.  The simplified transport of non-infectious material 




decisions at the country level regarding implementation of interventions to prevent further 
spread. 
Paper 2 demonstrates that the strains present in the 2014 outbreaks in South-east 
Asia are distinct from those in Africa.  In addition, the sequencing results revealed a distinct 
relationship between strains present in the 2014 outbreaks in Cameroon and those isolated 
from Mozambique in 2008.  This finding combined with the fact that the strains in the two 
outbreaks in distinct areas of the Far North of Cameroon in 2014 are similarly related 
suggests that continued molecular characterization in these areas and in Africa is needed 
to clarify the relationship among strains on the continent and disease transmission patterns. 
 
5.1.3. Paper III 
 
 Paper 3 presents the first cholera rapid risk assessment tool (RAT) to aid agencies 
and ministries for assessing the risk of a cholera outbreak in an endemic area.  The RAT 
details the step-by-step process for collating case and death data at the national, regional 
and district levels to include adjustments for missed cases and deaths.  The RAT also 
provides a tool for assessing risk in the absence of disease burden and death information 
by applying a weighted risk model to identify areas of high risk in the country.  The RAT 
is a simple tool applying readily available data while engaging the Ministry of Health; in 
comparison to the costs and time associated with setting up a prospective surveillance study, 
the RAT provides the information in a very short period of time.  The process of gathering 
the data for the RAT encourages discussion regarding cholera disease burden among 
decision makers and the Ministry of Health.  The RAT will hopefully provide evidence 




outbreaks. The RAT will continue to be improved through further application, currently 
being targeted for use in Nepal, Uganda and South Sudan in early 2015. 
 The RAT evaluation using data from the Republic of Kenya identified several 
provincial level and district level populations at high risk for cholera but with populations 
too large for vaccination consideration with the current vaccine availabilities.  Therefore, 
the use of the weighted risk factor algorithm demonstrated further stratification of risk 
among the districts to provide more refined guidance for the decision makers and Ministry 
of Health to consider as they evaluate vaccination and intervention strategies.  Given the 
detailed district level cholera surveillance information that was available for evaluation in 
the RAT in Kenya, it is likely that most countries may need to incorporate the use of risk 
factors for cholera in order to target cholera interventions to areas at greatest risk where 
cholera vaccination campaigns are financially and politically feasible. 
 
5.2. Study Limitations 
 
 The most important limitation of our investigation was the major security risks at 
our study site in the Far North of Cameroon.  Since shortly after our grant was awarded, 
the Boko Haram terrorist group has established themselves in the Far North region as well 
as in the communities and islands in Lake Chad.  Our study team has worked as diligently 
as possible in spite of on-going personal risk of harm.  Considering the obstacles, the study 
has been extremely successful.  However, these security and safety issues led to loss of 
data in some study areas, particularly Darak which is located in Lake Chad.  In paper 1 we 
detail the clinical and environmental surveillance among our study sites for the first 14 




the environmental sampling sites in and around the Darak sentinel site in the early months 
of 2014.  It is possible that the presence of these vibrios may have been an early warning 
sign for the area’s impending outbreak in October 2014; however, the team was unable to 
maintain regular surveillance in this area due to increased security risks and military 
intervention in the area.  While clinical cholera cases were confirmed in Darak health 
district in October 2014, there were only 2 additional clinical cases detected in the 
Blangoua health district for the period considered in paper 1.  Little analysis could be 
performed on the results of these clinical cases as only the 2 in Blangoua were detected 
during our regular study surveillance activities.  Therefore, we did not have the study size 
anticipated to conduct a case-control study in the area.  This limited positive sample size 
also likely negatively affected the reported dipstick sensitivity.  Finally, our laboratory 
diagnostics are only targeted to identify V. cholerae, and therefore, were unable to further 
characterize the cases of non-cholera diarrhea enrolled in the study to potentially evaluate 
the risk for adult diarrhea in the area. 
 The research and results supporting paper 2 were also limited as a result of security 
concerns.  Due to the inability to maintain regular surveillance in our study site, or to 
support cholera response efforts in the Bourrha Health district and surrounding areas, we 
were unable to collect samples from all suspected cholera cases.  In addition, we were 
unable to enroll all suspected cases into our study to collect epidemiological information 
to better characterize cholera risk in these situations.  However, the molecular 
characterization of the specimens collected demonstrated a very close relationship among 
strains analyzed.    Additionally, the relationship between the Cameroon strains and those 




comparison from Mozambique.  We are currently working to collaborate with a team in 
Mozambique to aide in their cholera disease surveillance and characterization. 
 The major limitation of the cholera RAT is that it has only been evaluated in one 
endemic country, the development of the tool will continue as the tool is applied in real-
time settings.  Currently, Nepal and South Sudan are considering targeted vaccination 
efforts utilizing vaccines supplied by the WHO stockpile.  We have on-going 
collaborations in each country and plan to evaluate the RAT in these settings. In addition, 
the RAT is limited by the quality of the data available in the country, at national, regional 
and district level.  If the data available is poor, the resulting assessment will be similarly 
of lower quality.  To ensure a quality assessment, the RAT must be conducted with 
cooperation from local decision-makers and health authorities. 
 While the dataset from the icddr,b utilized for the analysis in Paper 4 is a rich source 
of information, a retrospective surveillance cannot provide the same insight as a 
prospective case-control study to more clearly elucidate the risks of person-to-person 
transmission among neighbors.  In addition, it is not possible to clearly differentiate 
retrospectively whether transmission was truly person-to-person or from an environmental 
reservoir.  Based on statistical trends, we assume that large clustering of cases coincide 
with previous studies on person-to-person transmission.  Finally, due to the large size of 
the dataset in consideration, our statistical analysis took considerable time.  We will 
continue to explore this rich dataset to ensure that we have fully explored the study question 






5.3. Recommendations for future research 
 
 Continued research will be done to expand upon the findings of this dissertation.  
The clinical and environmental surveillance being conducted in the Far North of Cameroon 
will continue through 2016.   Cameroon has historically had years of little to no cholera 
incidence followed by several years of severe cholera disease.  During the first 14 months 
of our study, there was little V. cholerae 01 detected in the environmental or clinical aspects 
of our study.  Our original intent was to conduct a case-control study in this region to 
understand the risk factors as the dry, arid Sahel Desert is not the environment typically 
associated with endemic cholera.  As reported in Paper 2, clinical cholera was confirmed 
in the Far North region in May and June of 2014, near the Nigerian border and more 
recently it was confirmed in the Lake Chad area in and around our surveillance sites.  
Simultaneously to the outbreaks in the Cameroonian portion of Lake Chad, there was also 
an outbreak in the Lake Chad area of Chad.  The cholera outbreaks of 2009 in which 717 
cholera cases and 85 deaths (CFR 11.9%) were reported in the North and Far North of 
Cameroon (1) were much smaller than those in 2010 and 2011, in which a total of 27, 725 
cases including 1282 deaths (CFR, 4.6%) were reported (2).  With continued a continued 
surveillance program into 2015, we hope to be able to detect early signs of an outbreak and 
to aide in intervention strategies now to prevent outbreaks as large as those seen in 2010 
and 2011.  In addition, in Paper 1, we were unable to determine any seasonality examining 
nonpathogenic V. cholerae 01 patterns.  With continued surveillance, we hope to better 
understand if there truly is not a seasonality in this area.  Finally, as described in Paper 2, 




if the similar sequence type present in both outbreaks in 2014 is present due to its 
endemicity in the area or whether it was imported through travel/migration of people. 
 The cholera RAT will continue to be evaluated in endemic countries, globally, 
particularly those who have interest in vaccination campaigns in the coming year.  In 
addition, we plan to expand the cholera RAT to consider alternative scenarios in reactive 
and pre-emptive situations.  The current WHO stockpile minimum requirements for access 
to doses in the stockpile includes; the report of a culture-confirmed cholera case in a given 
area and the proposal to implement a reactive vaccination plan (3).  In addition, this year 
the Stockpile supplied vaccines for a pre-emptive vaccination approach in South Sudan (4).  
Countries that are currently accessing the stockpile need a risk assessment tool to aide in 
decision making regarding vaccination campaigns.  Recently, the WHO has begun seeking 
advice on developing a RAT for these various scenarios and we intend to work with them 
and other partners to adapt our tool for application in these settings. 
  
5.4 Policy Implications 
 
 This dissertation has several policy level implications for cholera surveillance and 
intervention strategies.  The findings from paper 1 and 2 demonstrate the successful 
application of simplified epidemiological surveillance methodologies and laboratory 
diagnostics to improve the capability and sustainability of cholera surveillance in even the 
most remote and vulnerable settings.  These findings may be expanded to enable 
surveillance in many other areas of Africa, and globally, where cholera disease burden 
remains uncharacterized.  Similarly, countries recognizing their cholera burden but without 




simplified methods to ensure either environmental and/or clinical cholera surveillance to 
improve their public health response networks. 
 Findings from paper 3 have policy implications for the strategic approach to cholera 
prevention and intervention programs, including vaccine campaigns.  Findings from paper 
3 suggest that while incidence rate and fatality rates are vital to targeting at risk areas, in 
the current state of limited vaccine availability, it is probable that most countries utilizing 
the RAT for risk assessment will have to employ the weighted risk factor approach to 
further guide their consideration of where to target high level interventions such as 
vaccination.  The WHO recognizes the need for this risk assessment tool, and have 
proposed the development of this tool to assess the risk and response to cholera in hotspots, 
as well as to define cholera control interventions.  The findings from Paper 3 will be shared 
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RESEARCH GRANT PARTICIPATION 
 
Title of Grant, Dates and Sponsoring Agency: “Delivering Oral Cholera Vaccine 
Effectively (DOVE)” – Bill and Melinda Gates Foundation. 2012-2016 
Principal Investigator and Funding Level:  David A Sack - $5 million over 4 years 
Main Grant Objective: To promote the effective use of oral cholera vaccine globally. 
Principal Responsibilities of Individual: Student Investigator to include development 
and evaluation of rapid and practical tools for OCV delivery, and to aide in management 
of epidemiological and laboratory surveillance in African countries engaged in 
surveillance. 
 
Title of Grant, Dates and Sponsoring Agency: “Immunologic assessment of vaccination 
and endemic infections from threat agent organisms in the countries of the former Soviet 
Union” – Chemical and Biological Defense: 2009-2011  
Principal Investigator and Funding Level: Matthew Hepburn - $150,000 
Main Grant Objective: To understand protective efficacy of vaccines in various endemic 
areas in the former Soviet Union. 
Principal Responsibilities of Individual: Associate Investigator and head of laboratory 
science aspects of the project. 
 
Title of Grant, Dates and Sponsoring Agency: “Anthrax Immunology of Primary 
Vaccinees in the Republic of Georgia” - Chemical and Biological Defense: 2005-2010 
Principal Investigator: Matthew Hepburn 
Main Grant Objective: To evaluate the effectiveness of anthrax vaccination in Georgia. 
Principal Responsibilities of Individual: U.S. Science lead - ELISA & Western Blotting 
assay development and testing; antigen cloning and production; Cell Mediated Immune 
Response diagnostic testing; data compilation and analysis; training for in-country 
personnel. 
 
Title of Grant, Dates and Sponsoring Agency: “Plague and Tularemia Immunology of 
Primary Vaccinees in the Republic of Georgia” - Chemical and Biological Defense: 
2006-2010 
Principal Investigator: Matthew Hepburn 





Principal Responsibilities of Individual: U.S. Science lead - ELISA & Western Blotting 
assay development and testing; antigen cloning and production; Cell Mediated Immune 
Response diagnostic testing; data compilation and analysis; training for in-country 
personnel. 
 
Title of Grant, Dates and Sponsoring Agency: “Retrospective Investigation of Anthrax 
infection Immune Profiles in the Republic of Georgia” - Chemical and Biological 
Defense: 2006-2013 
Principal Investigator: Robert Rivard 
Main Grant Objective: To improve the understanding of clinical anthrax infection 
immunology through a retrospective laboratory analysis of protection. 
Principal Responsibilities of Individual: U.S. Scientific support - ELISA & Western 
Blotting assay development and testing; antigen cloning and production; Cell Mediated 
Immune Response diagnostic testing; data compilation and analysis; training for in-
country personnel. 
 
Title of Grant, Dates and Sponsoring Agency: " Prospective Investigation of Anthrax 
infection Immune Profiles in the Republic of Georgia” - Chemical and Biological 
Defense: 2006-2013 
Principal Investigator: Robert Rivard 
Main Grant Objective: To prospectively evaluate persons infected with anthrax infection 
to better understand the immunological response during active infection. 
Principal Responsibilities of Individual: U.S. Scientific support - ELISA & Western 
Blotting assay development and testing; antigen cloning and production; Cell Mediated 
Immune Response diagnostic testing; data compilation and analysis; training for in-
country personnel. 
 
Title of Grant, Dates and Sponsoring Agency: " A Clinical Observational Study 
evaluating diagnostic modalities and case definitions for human brucellosis in Georgia” - 
Chemical and Biological Defense/Defense Threat Reduction Agency: 2007-2010 
Principal Investigator: Matthew Hepburn 
Main Grant Objective: To prospectively evaluate persons infected with brucellosis 
infection to compare Brucella diagnostics and to improve clinical case definitions in 
Georgia. 
Principal Responsibilities of Individual: U.S. Scientific support - ELISA and molecular 
laboratory training and support for in-country personnel; data compilation and analysis. 
 
Title of Grant, Dates and Sponsoring Agency: “A Clinical Observational Study 
evaluating diagnostic modalities and case definitions for human brucellosis in 
Azerbaijan” - Chemical and Biological Defense/Defense Threat Reduction Agency: 
2007-2011 
Principal Investigator: Matthew Hepburn 
Main Grant Objective: To prospectively evaluate persons infected with brucellosis 
infection to compare Brucella diagnostics and to improve clinical case definitions in 
Georgia. 
Principal Responsibilities of Individual: U.S. Scientific support - ELISA and molecular 





Title of Grant, Dates and Sponsoring Agency: “Acute Febrile Illness in the Republic of 
Georgia” - Global Emerging Infections Surveillance and Response System (GEIS): 2007-
2010 
Principal Investigator: Matthew Hepburn 
Main Grant Objective: To prospectively evaluate persons with Acute Febrile Illness of 
Unknown origin in Georgia. 
Principal Responsibilities of Individual: U.S. Scientific support - ELISA and support for 
in-country personnel; data compilation and analysis. 
 
Title of Grant, Dates and Sponsoring Agency: “Brucellosis Immunology” - Chemical 
and Biological Defense/United Kingdom Ministry of Defense: 2007-2010 
Principal Investigator: Matthew Hepburn and Huge Dyson 
Main Grant Objective: To prospectively evaluate persons with brucellosis to improve 
immunological understanding of disease progression in Georgia. 
Principal Responsibilities of Individual: U.S. Scientific support - ELISPOT, ELISA and 
Western Blot development, training and support for in-country personnel. 
 
Title of Grant, Dates and Sponsoring Agency: “A seroprevalence study of prior 
exposure to select arthropod-borne and zoonotic infections among rural populations in 
Northern Azerbaijan” - Defense Threat Reduction Agency: 2007-2010 
Principal Investigator: Matthew Hepburn  
Main Grant Objective: To conduct a retrospective seroprevalence study to improve 
understanding of arthropod-borne and zoonotic infections among the rural populations in 
Northern Azerbaijan. 
Principal Responsibilities of Individual: Associate Investigator - Scientific management, 
ELISA diagnostic development, training and support for in-country personnel; Data 
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Proficient in French; conversational Russian 
Proficient in use and application of : Stata, Tree-Age for economic modeling, Atlas.ti for 
qualitative analysis, ArcGIS 
Additional Experience in the use and application of R for Statistical computing and SAS 
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